Downloads: 1
[c09aa8]:
/
pdrdata.csv
| # | insulin lispro protamine (rDNA origin)/insulin lispro (rDNA origin) | ***For the treatment of type 1 diabetes mellitus or for type 2 diabetes mellitus inadequately managed by diet, exercise, and oral hypoglycemics. <br /> NOTE: A consensus algorithm issued by the ADA and the European Association for the Study of Diabetes lists basal or intermediate-acting insulin as a second line or third line agent in patients with type 2 diabetes not controlled on oral drugs; metformin is the initial recommended therapy in all type 2 diabetics without contraindications. Once insulin is added, therapy can be intensified (e.g., addition of prandial insulin) to achieve optimal glycemic control. In patients that are receiving a sulfonylurea, the sulfonylurea should be discontinued when insulin therapy is initiated.<br /> ***Formoterol; Mometasone | ***General Information***Diarrhea, fever, infection, surgery, thyroid disease, trauma, vomiting***Hepatic disease, renal failure, renal impairment***Coma, continuous subcutaneous insulin infusion (CSII) administration, diabetic ketoacidosis, hyperosmolar hyperglycemic state (HHS), intravenous administration***Hypoglycemia***Hypokalemia***Cresol hypersensitivity***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants***Tobacco smoking***Geriatric | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ['306266', '1546027'] | entecavir | ***For the treatment of chronic hepatitis B infection in patients with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (AST or ALT) or histologically active disease.***For the treatment of chronic hepatitis B in nucleoside-treatment-naive patients with compensated liver disease.***For treatment of chronic hepatitis B in patients with compensated liver disease and a history of hepatitis B viremia while receiving lamivudine or with known lamivudine or telbivudine resistance mutations (rtM204I/V with or without rtL180M, rtL80I/V, or rtV173L).***For the treatment of chronic hepatitis B in patients coinfected with HIV�. <br /> NOTE: Per HIV treatment guidelines, patients who are coinfected with hepatitis B virus (HBV) and human immunodeficiency virus (HIV), and who are unable to receive tenofovir, may use entecavir as an alternative; however, entecavir must be use in combination with a fully suppressive antiretroviral treatment regimen that includes either lamivudine or emtricitabine. HIV and HBV resistance may develop in a coinfected patient who is not receiving HAART and is taking entecavir. <br /> ***For the treatment of chronic hepatitis B in patients with decompensated liver disease. | ***Hepatitis B exacerbation***Hepatitis B and HIV coinfection, human immunodeficiency virus (HIV) infection***Organ transplant***Females, hepatic disease, hepatotoxicity or lactic acidosis, obesity***Dialysis, geriatric, renal failure, renal impairment***Children, infants, neonates***Breast-feeding***Pregnancy | |||||||||||||||||||||||||||||||
| 2 | ['60212'] | atovaquone | ***For the treatment of acute, mild to moderately-severe Pneumocystis pneumonia (PCP) infections in patients who do not tolerate trimethoprim-sulfamethoxazole.***For primary or secondary Pneumocystis pneumonia (PCP) prophylaxis.***For the acute treatment of toxoplasmic encephalitis� (toxoplasmosis�) due to <em>Toxoplasma gondii</em> in HIV-infected patients. <br /> NOTE: The FDA has designated atovaquone as an orphan drug for this indication.<br /> ***For toxoplasmosis prophylaxis�, specifically toxoplasmic encephalitis (TE), in HIV-infected patients. <br /> NOTE: The FDA has designated atovaquone as an orphan drug for this indication.<br /> ***For primary toxoplasmosis prophylaxis� in HIV-infected patients.***For secondary toxoplasmosis prophylaxis� (i.e., prevention of recurrent disease) in HIV-infected patients.***For the treatment of babesiosis� in combination with azithromycin. | ***General Information***GI disease***Infection, respiratory insufficiency***Pregnancy***Breast-feeding***Benzyl alcohol hypersensitivity, neonates***Hepatic disease | |||||||||||||||||||||||||||||||
| 3 | ['358274'] | ambrisentan | ***For improvement in exercise ability and delay in clinical worsening in patients with WHO Group I pulmonary hypertension (PAH). | ***Hepatic disease, hepatitis***Anemia***Geriatric, peripheral edema***Pulmonary edema, veno-occlusive disease (VOD)***Pulmonary fibrosis***Pregnancy***Breast-feeding***Contraception requirements, infertility, pregnancy testing, reproductive risk | |||||||||||||||||||||||||||||||
| 4 | ['60548'] | exenatide | ***For the treatment of type 2 diabetes mellitus in combination with diet and exercise. | ***General Information***Diabetic ketoacidosis, type 1 diabetes mellitus***Burns, diarrhea, fever, infection, surgery, thyroid disease, trauma, vomiting***Crohn's disease, gastroparesis, GI disease, inflammatory bowel disease, ulcerative colitis***Hypoglycemia***Dehydration, dialysis, kidney transplant, renal disease, renal failure, renal impairment***Tobacco smoking***Pregnancy***Breast-feeding***Children, infants***Pancreatitis***Medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN 2), thyroid cancer, thyroid C-cell tumors***Geriatric | |||||||||||||||||||||||||||||||
| 5 | ['9639'] | selegiline | ***For the treatment of Parkinson's disease or parkinsonism in combination with levodopa or levodopa/carbidopa.***For the treatment of major depression. | ***General Information***MAOI therapy***Alcoholism, ethanol ingestion, hypertension, hypertensive crisis***Pheochromocytoma***Children, suicidal ideation***Bipolar disorder, mania***Behavioral changes, psychosis, schizophrenia***Impulse control symptoms***Hypotension, orthostatic hypotension***Hepatic disease***Renal failure, renal impairment***Melanoma***Driving or operating machinery***Abrupt discontinuation***Pregnancy***Breast-feeding***Geriatric***Phenylketonuria***Ambient temperature increase, heating pad, sunlight (UV) exposure | |||||||||||||||||||||||||||||||
| 6 | ['3407'] | digoxin | ***For ventricular rate control in patients with chronic atrial fibrillation and/or atrial flutter�; or for the treatment of narrow-complex paroxysmal supraventricular tachycardia (PSVT)� or for paroxysmal supraventricular tachycardia (PSVT) prophylaxis� in patients without a delta wave on ECG during sinus rhythm; or for the treatment of congestive heart failure. <br /> NOTE: In patients with undetectable serum digoxin concentrations, the total loading dose should be based on lean body weight and clinical response, and divided into several doses administered at 4- to 8-hour intervals. Higher doses (i.e., concentrations) may be required for treating arrhythmias than for treating heart failure. Patients with moderate-severe renal insufficiency should receive smaller loading doses than patients with normal renal function due to a reduced volume of distribution.<br />NOTE: Maintenance doses should be based on lean body weight, clinical response, and renal function. Higher doses (i.e., concentrations) may be required for treating arrhythmias than for treating heart failure. Lower doses should be considered for geriatric patients, patients with impaired renal function, and in patients whose lean weight is an abnormally small fraction of their total body mass because of obesity or edema. In 1 small study of men with NYHA class II or III heart failure who were in normal sinus rhythm, left ventricular function improved significantly on a dose of 0.125 mg/day that produced mean serum concentrations of 0.8 ng/mL but doses of 0.25 mg/day and corresponding higher concentrations of 1.5 ng/mL did not produce further improvement over the lower dosage. In another small study of men with NYHA class II or III heart failure who were in normal sinus rhythm, left ventricular ejection fraction improved significantly when digoxin was increased from a mean dose of 0.2 mg/day (mean trough 0.67 ng/mL) to a mean dose of 0.39 mg/day (mean trough 1.22 ng/mL); however, no significant changes were observed in heart failure score or exercise tolerance***For the transplacental treatment of fetal supraventricular tachyarrhythmias�. | ***Acute myocardial infarction, Adams-Stokes syndrome, AV block, bradycardia, cardiomyopathy, cor pulmonale, hyperthyroidism, hypothyroidism, hypoxemia, myocarditis, myxedema, pulmonary disease, sick sinus syndrome***Carotid sinus hypersensitivity, ventricular arrhythmias, ventricular fibrillation, ventricular tachycardia, Wolff-Parkinson-White syndrome***Renal disease, renal failure, renal impairment***Geriatric***Hepatic disease***Constrictive pericarditis, idiopathic hypertrophic subaortic stenosis***Electrolyte imbalance, hypercalcemia, hyperkalemia, hypocalcemia, hypokalemia, hypomagnesemia***Hypertension***Infants, neonates, premature neonates***Pregnancy***Breast-feeding***Diarrhea, malabsorption syndrome***Intramuscular administration | |||||||||||||||||||||||||||||||
| 7 | valacyclovir hydrochloride | ***For the treatment of herpes simplex virus infection, including herpes labialis and herpes genitalis, and including HIV-infected patients�.***For the treatment of herpes labialis (i.e., cold sores).***For the treatment of initial episode of herpes genitalis.***For the treatment of recurrent herpes genitalis, including HIV-infected patients�.***For the treatment of herpes zoster (shingles) infection. <br /> NOTE: Valacyclovir is not approved for the treatment of disseminated herpes zoster infections.<br /***For the treatment of varicella (chickenpox) infection.***For the treatment of acute retinal necrosis (ARN)� due to varicella-zoster virus in HIV-infected patients.***For herpes genitalis prophylaxis or for secondary herpes simplex infection prophylaxis�.***For suppressive therapy of recurrent herpes genitalis in all patients or for secondary herpes simplex infection prophylaxis� in HIV-patients for frequent or severe recurrences.***For the reduction of transmission of genital herpes to an immunocompetent uninfected sex partner, in immunocompetent patients with a history of 9 or fewer recurrences per year.***For primary cytomegalovirus (CMV) disease prophylaxis�.***For primary cytomegalovirus (CMV) disease prophylaxis� in patients after kidney transplantation.***For primary cytomegalovirus (CMV) disease prophylaxis� in patients after bone marrow transplantation.***For primary cytomegalovirus (CMV) disease prophylaxis� in patients after heart transplantation.***For the treatment and prophylaxis of encephalitis� due to B virus (cercopithecine herpesvirus) infection�.***For the adjunctive treatment of Bell's palsy� in combination with steroids.***For post-exposure varicella (chickenpox) infection prophylaxis� to prevent primary infection in HIV-infected patients. | ***Acyclovir hypersensitivity, famciclovir hypersensitivity, ganciclovir hypersensitivity, penciclovir hypersensitivity, valacyclovir hypersensitivity, valganciclovir hypersensitivity***Renal failure, renal impairment***Geriatric***Dehydration***Children, infants, neonates***Pregnancy***Breast-feeding | ||||||||||||||||||||||||||||||||
| 8 | ['4083'] | drospirenone/ethinyl estradiol | ***For routine contraception.***For the treatment of acne vulgaris in women who also desire oral contraception.***For the treatment of premenstrual dysphoric disorder (PMDD) in women who also desire oral contraception.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, who have achieved menarche and desire contraception.***For the treatment or adjuvant treatment of conditions such as amenorrhea�, hirsutism�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who desire oral contraception.***Formoterol; Mometasone | ***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Adrenal insufficiency, electrolyte imbalance, hyperkalemia, renal disease, renal failure, renal impairment***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia, pancreatitis***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, hypertension, myocardial infarction, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema | |||||||||||||||||||||||||||||||
| 9 | U-500) (insulin human | ***For the treatment of type 1 diabetes mellitus or for type 2 diabetes mellitus inadequately managed by diet, exercise, and oral hypoglycemics.***For the treatment of gestational diabetes or for the treatment of patients with pre-existing diabetes mellitus (Type 1 or type 2) who are now pregnant.***For pregnant patients with gestational-onset diabetes not controlled by diet-therapy alone.***For pregnant patients with preexisting diabetes prior to pregnancy.***For the treatment of diabetic ketoacidosis (DKA).***For the treatment of hyperosmolar hyperglycemic state (HHS) in patients with type 2 diabetes mellitus.***For the treatment of neonatal diabetes mellitus�.***For nutritional supplementation� to maintain normoglycemia in very low birthweight infants with persistent glucose intolerance, including those neonates on parenteral nutrition with persistent glucose intolerance.***For the treatment of hyperkalemia�.***Formoterol; Mometasone | ***Diarrhea, fever, infection, surgery, thyroid disease, trauma, vomiting***Hepatic disease, renal failure, renal impairment***Intramuscular administration, intravenous administration***Continuous subcutaneous insulin infusion (CSII) administration***Hypoglycemia***Hypokalemia***Cresol hypersensitivity***Labor, neonates, obstetric delivery, pregnancy***Breast-feeding***Children, infants***Tobacco smoking***Geriatric | ||||||||||||||||||||||||||||||||
| 10 | salmeterol xinafoate | ***For the maintenance prevention of bronchospasm (e.g., bronchospasm prophylaxis) in patients with asthma.***For the treatment of asthma, including nocturnal asthma symptoms, in patients receiving optimum treatment with antiinflammatory asthma agents and who still require a inhaled beta-adrenergic bronchodilator on a regular schedule.***For exercise-induced bronchospasm prophylaxis.***For the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) including emphysema and chronic bronchitis.***For altitude sickness prophylaxis<strong>***Formoterol***Formoterol; Mometasone | ***General Information***Monotherapy treatment of asthma***Milk protein hypersensitivity***Acute bronchospasm, asthma-related death, status asthmaticus***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, QT prolongation, tachycardia***Diabetes mellitus, hyperthyroidism, pheochromocytoma, seizure disorder, seizures, thyroid disease, thyrotoxicosis***Labor, pregnancy***Breast-feeding***Children, infants***Hepatic disease***Paradoxical bronchospasm***MAOI therapy***Geriatric | ||||||||||||||||||||||||||||||||
| 11 | triamcinolone acetonide | ***For bronchospasm prophylaxis or maintenance therapy in patients who require chronic treatment with corticosteroids for control of bronchial asthma.***For the treatment of severe or incapacitating allergic conditions such as asthma that are intractable to adequate trials of conventional treatment.***For the treatment of symptoms of seasonal and perennial allergic rhinitis.***For the treatment of severe or incapacitating allergic conditions that are intractable to adequate trials of conventional treatment.***For the treatment of ocular inflammation (i.e., sympathetic ophthalmia and ocular inflammatory conditions unresponsive to topical corticosteroids), temporal arteritis, and uveitis.***For visualization during ocular surgery (i.e., vitrectomy).***For the treatment of acute rheumatic carditis, berylliosis, temporal arteritis�, or systemic lupus erythematosus (SLE). <br /> NOTE: For many conditions, the dosing of corticosteroids is highly variable; the following general dosing recommendations apply.<br /> ***For the treatment of pruritus and topical inflammation associated with moderate to severe corticosteroid-responsive dermatoses (e.g., alopecia areata, atopic dermatitis, contact dermatitis including <em>Rhus dermatitis</em> due to poison ivy, poison oak, poison sumac, subacute cutaneous or discoid lupus erythematosus, eczema, exfoliative dermatitis, insect bites or stings, granuloma annulare, keloids, lichen striatus, lichen planus, lichen simplex chronicus, mycosis fungoides, necrobiosis lipoidica diabeticorum, pemphigus, pityriasis rosea, polymorphous light eruption, psoriasis, sarcoidosis, seborrheic dermatitis, sunburn, or xerosis). <br /> NOTE: Occlusive dressings may be necessary for chronic or severe cases of psoriasis or other recalcitrant conditions.<br /> ***For the treatment of ulcerative or inflammatory oral lesions including aphthous ulcer, desquamative gingivitis�, and oral lichen planus�.***For the treatment of severe or incapacitating allergic conditions such as atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions, bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome) that are intractable to adequate trials of conventional treatment and for the treatment of idiopathic eosinophilic pneumonias.***For the treatment of symptomatic sarcoidosis.***For the treatment of primary (Addison's disease) or secondary adrenocortical insufficiency. <br /> NOTE: Hydrocortisone and cortisone are the preferred agents for these conditions.<br /> ***For the treatment of congenital adrenal hyperplasia.***For the treatment of hypercalcemia associated with cancer.***For the treatment of nonsuppurative thyroiditis.***For the treatment of a critical period of regional enteritis and ulcerative colitis.***For the treatment of autoimmune hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, or selected cases of secondary thrombocytopenia.***For the treatment of trichinosis with neurologic or myocardial involvement.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of acute exacerbations of multiple sclerosis. <br /> NOTE: Corticosteroids are effective in speeding the resolution of acute exacerbations, but they do not affect the ultimate outcome or natural history of the disease.<br /> ***For the treatment of cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury.***For the treatment of proteinuria or to induce diuresis in idiopathic nephrotic syndrome or lupus erythematosus.***For the treatment of an acute episode or exacerbation of ankylosing spondylitis, psoriatic arthritis, and juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA) as adjunctive therapy for short-term administration.***For the treatment of dermatomyositis or polymyositis.***For the relief of inflammation and for immunosuppression associated with a variety of disorders, like Hodgkin lymphoma. <br /> NOTE: For many conditions, the dosing of corticosteroids is highly variable; the following general dosing recommendations apply.<br /> ***For the palliative treatment of leukemias and lymphomas.***For the treatment of chronic immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP).***For the treatment of diabetic macular edema�.***For the relief of inflammation associated with synovitis of osteoarthritis; rheumatoid arthritis; acute and subacute bursitis; gout with acute gouty arthritis; epicondylitis; acute non-specific tenosynovitis; polychondritis�; posttraumatic osteoarthritis. <br /> NOTE: For many conditions, the dosing of corticosteroids is highly variable; the following general dosing recommendations apply.<br /> ***For the treatment of osteoarthritis pain of the knee. <br /> NOTE: Zilretta is not interchangeable with other formulations of triamcinolone acetonide.<br / | ***Epidural administration, intramuscular administration, intrathecal administration, intravenous administration, subcutaneous administration***Acute bronchospasm, status asthmaticus***Abrupt discontinuation, adrenal insufficiency, Cushing's syndrome, hyperthyroidism, hypothalamic-pituitary-adrenal (HPA) suppression, hypothyroidism, increased intracranial pressure, occlusive dressing, skin abrasion***Head trauma***Growth inhibition, osteoporosis***Surgery***Fungal infection, infection, viral infection***Tuberculosis***Immunosuppression***Herpes infection, measles, varicella***Glaucoma***Acne rosacea, acne vulgaris***Peripheral vascular disease***Nasal septal perforation, nasal surgery, nasal trauma***Myocardial infarction***Heart failure, hypertension***Diabetes mellitus***Skin atrophy***Diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Myasthenia gravis***Psychosis, seizure disorder***Coagulopathy, hemophilia, thromboembolic disease***Cataracts, ocular exposure, ocular infection, ophthalmic administration, visual disturbance***Pregnancy***Vaccination***Breast-feeding***Tartrazine dye hypersensitivity***Neonates, premature neonates***Idiopathic thrombocytopenic purpura (ITP)***Corticosteroid hypersensitivity***Geriatric***Renal disease, renal impairment***Hepatic disease | ||||||||||||||||||||||||||||||||
| 12 | ['3108'] | dapsone | ***For the treatment of dermatitis herpetiformis.***For the treatment leprosy (Hansen's disease).***For multibacillary leprosy.***For paucibacillary leprosy.***For the treatment of acne vulgaris.***For the treatment of actinomycotic mycetoma�.***For actinomycotic mycetoma� caused by <em>Actinomadura madurae</em>� or <em>Streptomyces somaliensis</em>�.***For actinomycotic mycetoma� caused by <em>Nocardia</em> sp.�.***For the treatment of granuloma annulare�.***For the treatment of chronic immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP)�.***For the treatment of polychondritis�.***For the treatment of mild to moderate Pneumocystis pneumonia (PCP)�.***For Pneumocystis pneumonia (PCP) prophylaxis�.***For primary PCP prophylaxis� in HIV-infected patients.***For secondary PCP prophylaxis� in HIV-infected patients after PCP treatment.***For primary toxoplasmosis prophylaxis� in HIV-infected patients, specifically prevention of toxoplasmic encephalitis (TE)� due to <em>Toxoplasmosis gondii</em>.***For the treatment of pyoderma gangrenosum�.***For the treatment of subcorneal pustular dermatosis�. | ***Anemia, G6PD deficiency, methemoglobin reductase deficiency***Hepatic disease***Pregnancy***Breast-feeding***Children, infants, neonates***Sulfonamide hypersensitivity | |||||||||||||||||||||||||||||||
| 13 | fluticasone propionate | ***For the treatment of pruritus and topical inflammation associated with moderate to severe corticosteroid-responsive dermatoses, including the treatment of alopecia areata, discoid lupus erythematosus, generalized exfoliative dermatitis, cutaneous lichen planus, lichen simplex chronicus, lichen striatus, nodular prurigo, pompholyx (dyshidrosis), pemphigus, polymorphous light eruption, psoriasis, seborrheic dermatitis, severe contact dermatitis, severe Rhus dermatitis (due to plants like poison ivy), and xerosis.***For the treatment of eczema, including atopic dermatitis.***For the management of symptoms associated with seasonal or perennial allergic rhinitis, including allergic conjunctivitis.***For the management of nasal symptoms associated with vasomotor rhinitis (perennial nonallergic rhinitis).***For the maintenance treatment of asthma.***For the treatment of nasal polyps.***For exercise-induced bronchospasm prophylaxis�.***Formaldehyde hypersensitivit | ***General Information***Corticosteroid hypersensitivity, milk protein hypersensitivity***Acute bronchospasm, status asthmaticus***Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion, surgery***Diabetes mellitus***Nasal septal perforation, nasal surgery, nasal trauma***Fungal infection, herpes infection, infection, measles, tuberculosis, varicella, viral infection***Malnutrition, osteoporosis, tobacco smoking***Geriatric***Hepatic disease***Acne rosacea, acne vulgaris, perioral dermatitis, peripheral vascular disease, skin atrophy***Cataracts, glaucoma, increased intraocular pressure, ocular exposure***Formaldehyde hypersensitivity***Children, growth inhibition, increased intracranial pressure, infants***Pregnancy***Breast-feeding***Sunlight (UV) exposure | ||||||||||||||||||||||||||||||||
| 14 | pramlintide acetate | ***For the treatment of type 1 diabetes mellitus and type 2 diabetes mellitus.***For the adjunct treatment of type 1 diabetes mellitus in patients who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy.***For the adjunct treatment of type 2 diabetes mellitus in patients who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy. | ***General Information***Gastroparesis***Dialysis, renal failure***Driving or operating machinery, hypoglycemia***Cresol hypersensitivity***Diarrhea, fever, infection, surgery, thyroid disease, trauma, vomiting***Osteoporosis***Pregnancy***Breast-feeding***Children***Tobacco smoking***Geriatric | ||||||||||||||||||||||||||||||||
| 15 | diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated poliovirus vaccine | ***For simultaneous diphtheria prophylaxis, tetanus prophylaxis, pertussis prophylaxis, hepatitis B prophylaxis, and poliovirus prophylaxis for primary immunization. | ***General Information***Hepatitis***Anticoagulant therapy, coagulopathy, hemophilia, intraarterial administration, intravenous administration, subcutaneous administration, thrombocytopenia, vitamin K deficiency***Children, geriatric, infants, neonates, premature neonates***Neomycin hypersensitivity, polymyxin hypersensitivity, yeast hypersensitivity***Latex hypersensitivity***Fever, shock***Coma, encephalopathy, neurological disease, seizure disorder, seizures***Guillain-Barre syndrome***Chemotherapy, immunosuppression, radiation therapy***Pregnancy***Breast-feeding | ||||||||||||||||||||||||||||||||
| 16 | ['28439'] | lamotrigine | ***For the treatment of partial seizures with or without secondary generalization. <br /> NOTE: Lamotrigine should be initiated at a low dose, with gradual increases according to the dose escalation guidelines provided by the manufacturer. This may minimize the occurrence of a severe, and potentially life-threatening skin rash, which has been associated with lamotrigine administration.<br />NOTE: Therapeutic plasma concentrations have not been established. In general, dosage should be based upon clinical response.<br />NOTE: Discontinuation of lamotrigine should be done in a step-wise fashion over at least 2 weeks (approximately 50% dosage reduction per week), unless safety concerns warrant a more rapid withdrawal***For monotherapy of partial seizures in patients currently receiving treatment with a single enzyme-inducing anti-epileptic drug (AED) (e.g., carbamazepine, phenobarbital, phenytoin, primidone) NOT to include valproate.***For monotherapy of partial seizures in patients currently receiving treatment with valproate.***For adjunctive therapy to other anticonvulsants in the treatment of partial seizures.***For monotherapy of partial seizures in patients currently receiving treatment with a single anti-epileptic drug (AED) OTHER than carbamazepine, phenytoin, phenobarbital, primidone, or valproate. <br /> NOTE: Safety and effectiveness of extended-release tablets have not been established as initial monotherapy or for simultaneous conversion to monotherapy from 2 or more concomitant AEDs.<br /***For adjunctive therapy to other anticonvulsants in the treatment of primary generalized tonic-clonic seizures. <br /> NOTE: Lamotrigine should be initiated at a low dose, with gradual increases according to the dose escalation guidelines provided by the manufacturer. This may minimize the occurrence of a severe, and potentially life-threatening skin rash, which has been associated with lamotrigine administration.<br />NOTE: Therapeutic plasma concentrations have not been established. In general, dosage should be based upon clinical response.<br />NOTE: Discontinuation of lamotrigine should be done in a step-wise fashion over at least 2 weeks (approximately 50% dosage reduction per week), unless safety concerns warrant a more rapid withdrawal***For adjunctive therapy to other anticonvulsants in the treatment of generalized seizures of Lennox-Gastaut syndrome. <br /> NOTE: Lamotrigine should be initiated at a low dose, with gradual increases according to the dose escalation guidelines provided by the manufacturer. This may minimize the occurrence of a severe, and potentially life-threatening skin rash, which has been associated with lamotrigine administration.<br />NOTE: Therapeutic plasma concentrations have not been established. In general, dosage should be based upon clinical response.<br />NOTE: Discontinuation of lamotrigine should be done in a step-wise fashion over at least 2 weeks (approximately 50% dosage reduction per week), unless safety concerns warrant a more rapid withdrawal***For the long-term maintenance treatment of bipolar disorder (bipolar I disorder) to delay the occurrence of mood episodes (i.e., depression, mania, hypomania, mixed episodes) in patients treated for acute mood episodes with standard therapy. <br /> NOTE: Do not exceed initial and subsequent dose escalations of lamotrigine due to increased risk of rash. Periodically re-assess the need for continued treatment. Lamotrigine should not be abruptly discontinued; taper downward roughly 50% per week for 2 weeks unless safety issues require a more rapid dose reduction.<br /> ***For the treatment of absence seizures�.***For long-term prophylaxis of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT)�. | ***General Information***Serious rash***Depression, suicidal ideation***Abrupt discontinuation***Driving or operating machinery***Hepatic disease***Dialysis, renal disease, renal failure, renal impairment***Cardiac disease, heart failure***Black patients***Geriatric***Children, infants, neonates***Folate deficiency, pregnancy***Breast-feeding | |||||||||||||||||||||||||||||||
| 17 | ['318341'] | cetuximab | ***For the treatment of KRAS wild-type metastatic colorectal cancer. <br /> NOTE: Cetuximab is not indicated for the treatment of RAS mutant colorectal cancer or when the results of RAS mutation tests are unknown. The absence of a RAS mutation should be confirmed by an FDA approved test prior to starting therapy.<br />NOTE: The serine-threonine kinase BRAF is the principal effector of KRAS. The introduction of the mutant BRAF V600E allele may impair therapeutic response to EGFR inhibitors. Mutant BRAF may be present in wild-type KRAS***For the treatment of KRAS wild-type, EGFR-expressing, metastatic colorectal cancer (mCRC) as a single agent after failure of both irinotecan- and oxaliplatin-based regimens or in patients who are intolerant to irinotecan-based chemotherapy. <br /> NOTE: In the clinical trials, patients were required to have immunohistochemical evidence of positive EGFR expression from primary tumor or metastatic tumor site using the DakCytomation EGFR pharmDx test kit. Response rate did not correlate with either the percentage of positive cells or the intensity of EGFR expression. EGFR expression status should be determined by an FDA approved test prior to starting therapy.<br /> ***For the treatment of KRAS wild-type, EGFR-expressing, metastatic colorectal cancer (mCRC) in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy. <br /> NOTE: In the clinical trials, patients were required to have immunohistochemical evidence of positive EGFR expression from primary tumor or metastatic tumor site using the DakCytomation EGFR pharmDx test kit. Response rate did not correlate with either the percentage of positive cells or the intensity of EGFR expression. EGFR expression status should be determined by an FDA approved test prior to starting therapy.<br /> ***For the first-line treatment of KRAS wild-type, EGFR-expressing, metastatic colorectal cancer (mCRC) in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin). <br /> NOTE: In the clinical trials, patients were required to have immunohistochemical evidence of positive EGFR expression from primary tumor or metastatic tumor site using the DakCytomation EGFR pharmDx test kit. Response rate did not correlate with either the percentage of positive cells or the intensity of EGFR expression. EGFR expression status should be determined by an FDA approved test prior to starting therapy.<br /> ***For the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC), in combination with mFOLFOX6 (leucovorin, oxaliplatin, 5-fluorouracil)�. <br /> NOTE: Response rates do not correlate with either the percentage of EGFR-positive cells or the intensity of EGFR expression.<br /> ***For the treatment of BRAF mutation-positive, RAS wild-type, metastatic colorectal cancer, in combination with irinotecan and vemurafenib�.***For the treatment of head and neck cancer. <br /> NOTE: Pretreatment assessment for evidence of EGFR expression is not required for patients with squamous cell cancer of the head and neck.<br />NOTE: Progression-free survival was not improved when cetuximab was added to radiation therapy and cisplatin for the treatment of locally advanced squamous cell carcinoma of the head and neck in a controlled study (n = 940); grade 3 and 4 toxicity and adverse reactions with fatal outcomes occurred more often in cetuximab-treated patients in this study***For the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck in combination with cisplatin�.***For the first-line treatment of recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy and fluorouracil.***For the first-line treatment of advanced non-small cell lung cancer (NSCLC)� in combination with cisplatin and vinorelbine. | ***Acute bronchospasm, hypotension, infusion-related reactions, murine protein hypersensitivity, urticaria***Pulmonary disease, pulmonary edema, pulmonary fibrosis***Infection, sunlight (UV) exposure***Cardiac arrest, cardiac arrhythmias, cardiac disease, coronary artery disease, electrolyte imbalance, heart failure, hypocalcemia, hypokalemia, hypomagnesemia, radiation therapy, respiratory arrest***Male-mediated teratogenicity, pregnancy***Breast-feeding***Children***KRAS mutations | |||||||||||||||||||||||||||||||
| 18 | fluticasone furoate | ***For the treatment of pruritus and topical inflammation associated with moderate to severe corticosteroid-responsive dermatoses, including the treatment of alopecia areata, discoid lupus erythematosus, generalized exfoliative dermatitis, cutaneous lichen planus, lichen simplex chronicus, lichen striatus, nodular prurigo, pompholyx (dyshidrosis), pemphigus, polymorphous light eruption, psoriasis, seborrheic dermatitis, severe contact dermatitis, severe Rhus dermatitis (due to plants like poison ivy), and xerosis.***For the treatment of eczema, including atopic dermatitis.***For the management of symptoms associated with seasonal or perennial allergic rhinitis, including allergic conjunctivitis.***For the management of nasal symptoms associated with vasomotor rhinitis (perennial nonallergic rhinitis).***For the maintenance treatment of asthma.***For the treatment of nasal polyps.***For exercise-induced bronchospasm prophylaxis�.***Formaldehyde hypersensitivit | ***General Information***Corticosteroid hypersensitivity, milk protein hypersensitivity***Acute bronchospasm, status asthmaticus***Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion, surgery***Diabetes mellitus***Nasal septal perforation, nasal surgery, nasal trauma***Fungal infection, herpes infection, infection, measles, tuberculosis, varicella, viral infection***Malnutrition, osteoporosis, tobacco smoking***Geriatric***Hepatic disease***Acne rosacea, acne vulgaris, perioral dermatitis, peripheral vascular disease, skin atrophy***Cataracts, glaucoma, increased intraocular pressure, ocular exposure***Formaldehyde hypersensitivity***Children, growth inhibition, increased intracranial pressure, infants***Pregnancy***Breast-feeding***Sunlight (UV) exposure | ||||||||||||||||||||||||||||||||
| 19 | tenofovir disoproxil fumarate | ***For the treatment of human immunodeficiency virus (HIV) infection in combination with other anti-retroviral agents.***For treatment of chronic hepatitis B infection.***For human immunodeficiency virus (HIV) prophylaxis�.***For human immunodeficiency virus (HIV) prophylaxis� after occupational exposure.***For human immunodeficiency virus (HIV) prophylaxis� after nonoccupational exposure, including sexual assault. <br /> NOTE: Higher risk exposures for which prophylaxis is recommended include exposure of vagina, rectum, eye, mouth, or other mucous membrane, nonintact skin, or percutaneous contact with blood, semen, vaginal secretions, rectal secretions, breast milk, or any body fluid that is visibly contaminated with blood when the source is known to be HIV-positive. Exposures to a source patient with unknown HIV status should be assessed on a case-by-case basis.<br /> ***For pre-exposure HIV prophylaxis� of uninfected individuals to reduce the risk of sexually acquired HIV in heterosexual adults at high risk and to reduce the acquisition risk of HIV in adult injection drug users. | ***General Information***Bone fractures, hypophosphatemia, renal failure, renal impairment***Osteomalacia, osteoporosis***Geriatric***Children, infants, neonates***Alcoholism, females, hepatic disease, hepatotoxicity or lactic acidosis, obesity***Pregnancy***Breast-feeding***Hepatitis B and HIV coinfection, hepatitis B exacerbation***Human immunodeficiency virus (HIV) infection resistance***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***HIV serum status***Hepatitis C and HIV coinfection | ||||||||||||||||||||||||||||||||
| 20 | sodium chloride | ***For the treatment of dehydration or hypovolemia, including during diabetic ketoacidosis, cardiopulmonary resuscitation, and shock (e.g., septic shock, anaphylactic shock, cardiogenic shock).***For the treatment of hyponatremia. <br /> NOTE: In general, initial correction of acute or symptomatic hyponatremia should be undertaken with hypertonic 3% Sodium Chloride Injection. Asymptomatic, chronic hyponatremia should be corrected with isotonic 0.9% Sodium Chloride Injection. <br /> ***For mucolysis and sputum induction in patients with cystic fibrosis.***For the treatment of nasal congestion and dryness.***For nutritional supplementation.***For temporary relief of corneal edema (i.e., ocular inflammation).***For the treatment of increased intracranial pressure�.***For the inpatient management of viral bronchiolitis�.***Formoterol; Mometasone | ***Cardiac disease, diabetic ketoacidosis, edema, heart failure, hyperaldosteronism, hyperchloremia, hypernatremia, hypertension, hypervolemia, metabolic acidosis, renal artery stenosis, renal disease, renal failure, renal impairment***Alcoholism, females, hyponatremia, hypoxemia, malnutrition***Hepatic disease***Hemolysis***Pregnancy***Breast-feeding***Neonates, premature neonates***Requires an experienced clinician***Visual impairment***Geriatric | ||||||||||||||||||||||||||||||||
| 21 | warfarin sodium | ***For general dosing information in patients requiring warfarin anticoagulation. <br /> NOTE: Clinical practice guidelines recommend against the routine use of pharmacogenetic testing for guiding dosing in patients initiating warfarin therapy.<br /> ***For treatment of deep venous thrombosis (DVT) or pulmonary embolism and deep vein thrombosis (DVT) prophylaxis or pulmonary embolism prophylaxis.***For the treatment and further prevention of DVT or pulmonary embolism (PE) after the initial, acute phase of treatment.***For DVT prophylaxis in patients undergoing total hip or knee replacement surgery or hip fracture surgery�.***For DVT prophylaxis in patients with long-term indwelling central venous catheters to prevent axillary-subclavian venous thrombosis�.***For thrombosis prophylaxis (i.e., arterial thromboembolism prophylaxis, stroke prophylaxis, or coronary artery thrombosis prophylaxis). <br /> NOTE: For information regarding prophylaxis in orthopedic surgery or with central venous catheters, see 'deep venous thrombosis (DVT) prophylaxis'.<br /> ***For coronary artery thrombosis prophylaxis in high or very high-risk patients with stable angina� or chronic coronary artery disease�.***For thrombosis prophylaxis in patients with atrial fibrillation.***For thrombosis prophylaxis in patients with atrial fibrillation or atrial flutter who are undergoing cardioversion.***For thrombosis prophylaxis in patients with prosthetic heart valves.***For thrombosis prophylaxis in patients with mechanical prosthetic heart valves and a history of bleeding while receiving warfarin therapy.***For stroke prophylaxis in patients with cerebral venous sinus thrombosis (CVST) after primary treatment with heparin or LMWH.***For thrombosis prophylaxis in patients with valvular heart disease.***For stroke prophylaxis in patients with dilated cardiomyopathy (DCM), particularly in the subgroup of patients with concomitant atrial fibrillation or with a prior history of systemic embolization.***For secondary myocardial infarction prophylaxis (i.e., prevention of a subsequent myocardial infarction or coronary artery thrombosis prophylaxis) or for stroke prophylaxis in high-risk postmyocardial infarction patients (e.g., patients with acute MI complicated by severe LV dysfunction, CHF, atrial fibrillation, previous emboli, or 2D echocardiograph evidence of mural thrombosis).***For the coronary artery thrombosis prophylaxis in patients with unstable angina�.***For prophylaxis of arterial and/or venous thromboembolism in patients with antiphospholipid antibody syndrome.***For thromboprophylaxis� in patients with heart failure� who are in sinus rhythm. | ***Coumarin anticoagulants hypersensitivity***Anemia, aneurysm, aortic dissection, atrial fibrillation, bleeding, cardiac disease, cerebrovascular disease, eclampsia, endocarditis, epidural anesthesia, GI bleeding, head trauma, hematological disease, hemophilia, hypertension, intracranial bleeding, leukemia, lumbar puncture, neoplastic disease, peptic ulcer disease, pericardial effusion, pericarditis, polycythemia vera, preeclampsia, renal disease, renal failure, renal impairment, retinal bleeding, spinal anesthesia, stroke, surgery, vasculitis***Asian patients***Dental work***Diabetes mellitus***Heparin-induced thrombocytopenia (HIT), idiopathic thrombocytopenic purpura (ITP)***Heart failure***Cholestasis, hepatic disease, hepatitis, jaundice***Intramuscular injections***Protein C deficiency, protein S deficiency***Vitamin C deficiency***Anorexia nervosa, bulimia nervosa, vitamin K deficiency***Alcoholism, dementia, psychosis***Fever, hyperthyroidism, infection***Diarrhea, hyperlipidemia, hypothyroidism, peripheral edema***Tobacco smoking***Geriatric***Labor, obstetric delivery, pregnancy***Children, infants, neonates***Breast-feeding***Contraception requirements, pregnancy testing, reproductive risk | ||||||||||||||||||||||||||||||||
| 22 | bupropion hydrochloride | ***For the treatment of major depression.***For the prevention of seasonal major depressive disorder episodes associated with seasonal affective disorder (SAD).***For use as an adjunct to psychosocial interventions in the management of tobacco cessation (smoking cessation).***For use alone to aide in tobacco cessation.***For aide with tobacco cessation using bupropion in combination with a nicotine transdermal system (NTS).***For the treatment of attention-deficit hyperactivity disorder (ADHD)�.***For use as monotherapy of attention-deficit hyperactivity disorder (ADHD)� in adults.***For the symptomatic treatment of neuropathic pain� due to various causes, including pain associated with peripheral diabetic neuropathy� or postherpetic neuralgia�.***Formoterol; Mometasone | ***General Information***Alcoholism, anorexia nervosa, benzodiazepine withdrawal, brain tumor, bulimia nervosa, diabetes mellitus, head trauma, hypoglycemia, hyponatremia, hypoxemia, intracranial mass, obesity treatment, seizure disorder, seizures, stroke, substance abuse***Children, suicidal ideation***Tics, Tourette's syndrome***Behavioral changes, bipolar disorder, depression, mania, psychiatric event, schizophrenia***MAOI therapy***Neonates, pregnancy***Breast-feeding***Hepatic disease***Renal disease, renal failure, renal impairment***Acute myocardial infarction, cardiac disease, heart failure, hypertension, tobacco smoking***Geriatric***Driving or operating machinery, ethanol intoxication***Closed-angle glaucoma, increased intraocular pressure***Abrupt discontinuation | ||||||||||||||||||||||||||||||||
| 23 | ['613391'] | prasugrel | ***For arterial thromboembolism prophylaxis (thrombotic cardiovascular events including stent thrombosis) in patients with acute coronary syndrome (i.e., unstable angina, non-ST-elevation myocardial infarction [NSTEMI], or ST-elevation acute myocardial infarction [STEMI]) who are to be managed with percutaneous coronary intervention (PCI). | ***Anticoagulant therapy, bleeding, body weight less than 60 kg, coronary artery bypass graft surgery (CABG), GI bleeding, intracranial bleeding, peptic ulcer disease, surgery, trauma***Stroke***Hepatic disease***Thrombotic thrombocytopenic purpura (TTP)***Abrupt discontinuation***Asian patients***Children***Pregnancy***Breast-feeding***Renal impairment***Thienopyridine hypersensitivity***Geriatric | |||||||||||||||||||||||||||||||
| 24 | ['4083'] | drospirenone/ethinyl estradiol | ***For routine contraception.***For the treatment of acne vulgaris in women who also desire oral contraception.***For the treatment of premenstrual dysphoric disorder (PMDD) in women who also desire oral contraception.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, who have achieved menarche and desire contraception.***For the treatment or adjuvant treatment of conditions such as amenorrhea�, hirsutism�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who desire oral contraception.***Formoterol; Mometasone | ***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Adrenal insufficiency, electrolyte imbalance, hyperkalemia, renal disease, renal failure, renal impairment***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia, pancreatitis***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, hypertension, myocardial infarction, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema | |||||||||||||||||||||||||||||||
| 25 | ['197'] | acetylcysteine | ***For the prevention of hepatotoxicity after an acute acetaminophen overdose or repeated ingestion of supratherapeutic doses. <br /> NOTE: The Rumack-Matthew nomogram should be used to estimate the hepatotoxicity potential from an acute acetaminophen (APAP) overdose in patients with a known APAP concentration, a known APAP ingestion time, and who present within 8 hours of the overdose. For patients whose serum APAP concentrations fall above the possible" toxicity line on the nomogram | initiate treatment within 8 hours of suspected APAP ingestion for maximal protection against hepatic injury. Give activated charcoal as soon as possible after ingestion to prevent APAP absorption. For regular-release APAP overdoses | obtain serum drug concentration at least 4 hours post-ingestion; concentrations obtained earlier than 4 hours may not represent maximum APAP concentrations. For extended-release APAP overdoses | if the initial APAP serum concentration was below the possible toxicity line | obtain a second concentration 8 to 10 hours post-ingestion. The efficacy of acetylcysteine diminishes progressively after 8 hours post-ingestion. Beginning treatment 15 to 24 hours post-ingestion results in limited efficacy; however | it does not appear to worsen the condition and should not be withheld since the reported time of ingestion may not be correct. If the time of ingestion is unknown | or the serum APAP concentration is not available | cannot be interpreted | or is not available within 8 hours of APAP ingestion | acetylcysteine should be administered immediately regardless of the quantity reported to have been ingested. If greater than 24 hours has elapsed since the APAP ingestion | the clinician should determine the appropriateness of acetylcysteine administration based on the patients liver status and clinical presentation.<br />NOTE: The Rumack-Matthew nomogram is ineffective at predicting hepatotoxicity in patients who have ingested repeated supratherapeutic doses of acetaminophen over an extended period of time. In these patients | treatment should be guided by information obtained from laboratory tests | including: acetaminophen serum concentrations | liver function tests (LFTs) | serum creatinine | BUN | electrolytes | bilirubin | blood glucose | and INR. Assistance may be obtained by contacting your regional poison control center at 1�800�222�1222 or the acetaminophen overdose center at 1�800�525�6115.***For adjunctive treatment of chronic bronchopulmonary disorders such as chronic obstructive pulmonary disease (COPD) | including chronic bronchitis | emphysema | tuberculosis | bronchiectasis | and primary amyloidosis of the lung.***For mucolysis of viscous or inspissated mucous secretions in patients with pulmonary conditions (e.g. | pneumonia | bronchitis | cystic fibrosis | atelectasis due to mucous obstruction | and post-traumatic chest conditions) and for use during tracheostomy care | anaesthesia | and diagnostic bronchograms.***For diagnostic bronchial studies.***For nephrotoxicity prophylaxis� against radiographic-contrast-induced reductions in renal function in those patients with preexisting renal insufficiency (SCr > 1.2mg/dl or CrCl < 60 ml/min) or who are otherwise at risk for radiocontrast-induced nephropathy.***For the treatment of giant papillary conjunctivitis (GPC)�.***For the treatment of distal intestinal obstruction syndrome (DIOS)� (previously called meconium ileus equivalent)." | ***General Information***Acute bronchospasm, asthma, gag reflex depression, respiratory insufficiency***Esophageal varices, GI bleeding, peptic ulcer disease, vomiting***Children, infants, neonates***Pregnancy***Breast-feeding***Heart failure, hypertension, renal disease |
| 26 | ['2105', '343027'] | carmustine | ***For the treatment of brain tumors including malignant glioma and glioblastoma multiforme.***For the treatment of brain tumors including malignant glioma, glioblastoma, medulloblastoma, astrocytoma, ependymoma, and brain metastases. <br /> NOTE: Carmustine injection has been designated an orphan drug by the FDA for the treatment of intracranial malignancies.<br /***For the treatment of newly-diagnosed high grade malignant glioma as an adjunct to surgery and radiation and as an adjunct to surgery in patients with recurrent glioblastoma multiforme. <br /> NOTE: Carmustine implantable wafer has been designated an orphan drug by the FDA for the treatment of malignant glioma.<br /***For the treatment of multiple myeloma in combination with prednisone.***For the treatment of relapsed or refractory Hodgkin lymphoma or non-Hodgkin's lymphoma (NHL), in combination with other approved drugs.***For the first-line treatment of metastatic malignant melanoma in combination with dacarbazine, cisplatin, and tamoxifen�. <br /> NOTE: Since the major toxicity associated with carmustine administration is delayed bone marrow suppression, blood counts should be monitored weekly for at least 6 weeks after a dose and courses of carmustine should not be given more frequently than every 6 weeks.<br /> ***For the treatment of cutaneous T-cell lymphoma (CTCL)� (aka mycosis fungoides�).***For stem cell transplant preparation, in combination with other chemotherapy agents�.***Formoterol; Mometasone | ***General Information***Anemia, aseptic meningitis, bleeding, bone marrow suppression, infection, leukopenia, neutropenia, thrombocytopenia***Pulmonary fibrosis, pulmonary toxicity***New primary malignancy***Extravasation***Intraarterial administration***Seizures***Wound dehiscence***Increased intracranial pressure***Renal disease, renal failure, renal impairment***Hepatic disease, hepatotoxicity***Children***Pregnancy***Contraception requirements, infertility, male-mediated teratogenicity, reproductive risk***Breast-feeding | |||||||||||||||||||||||||||||||
| 27 | influenza vaccine | ***For annual seasonal influenza prophylaxis. | ***General Information***Intravenous administration, subcutaneous administration***Fever, respiratory infection***Egg hypersensitivity, kanamycin hypersensitivity, latex hypersensitivity, neomycin hypersensitivity***Guillain-Barre syndrome***Geriatric***Children, infants***Pregnancy***Breast-feeding***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Acquired immunodeficiency syndrome (AIDS), agammaglobulinemia, human immunodeficiency virus (HIV) infection, hypogammaglobulinemia, immunosuppression, neoplastic disease, radiation therapy, severe combined immunodeficiency (SCID)***Syncope | ||||||||||||||||||||||||||||||||
| 28 | ['475342', '1546019'] | dasatinib | ***For the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). <br /> NOTE: The FDA has designated dasatinib as an orphan drug for the treatment of CML.<br /> ***For the treatment of myeloid or lymphoid blast-phase Ph+ CML with resistance or intolerance to prior therapy, including imatinib.***For the treatment of chronic-phase Ph+ CML with resistance or intolerance to prior therapy, including imatinib.***For the treatment of newly diagnosed chronic-phase Ph+ CML. <br /> NOTE: Dasatinib was not active against the T315I mutation based on in vitro data.<br /> ***For the treatment of accelerated-phase Ph+ CML with resistance or intolerance to prior therapy, including imatinib.***For the treatment of chronic-phase Ph+ CML.***For the treatment of Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL). <br /> NOTE: Dasatinib has been designated as an orphan drug by the FDA for the treatment of Ph+ ALL.<br /***For the treatment of For the treatment of Ph+ ALL with resistance or intolerance to prior therapy.***Formoterol***Formoterol; Mometasone | ***Anemia, bone marrow suppression, neutropenia, thrombocytopenia***Anticoagulant therapy, bleeding, GI bleeding, intracranial bleeding***Edema, pericardial effusion, pleural effusion***Alcoholism, cardiac arrhythmias, cardiac disease, diabetes mellitus, females, heart failure, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, QT prolongation, thyroid disease***Lactase deficiency***Tumor lysis syndrome (TLS)***Pulmonary hypertension***Geriatric***Children, growth inhibition, infants, neonates***Pregnancy***Contraception requirements, infertility, reproductive risk***Breast-feeding | |||||||||||||||||||||||||||||||
| 29 | ['35636'] | risperidone | ***For the treatment of schizophrenia.***For the treatment of bipolar disorder (Bipolar I Disorder), including acute mania or mixed episodes and maintenance therapy.***For the treatment of acute mania or mixed episodes associated with Bipolar I Disorder.***For the maintenance treatment of Bipolar I Disorder as monotherapy or adjunct therapy to lithium or valproate.***For the treatment of irritability associated with autistic disorder.***For the treatment of moderate to severe tics associated with Tourette's syndrome�.***For the treatment of moderate to severe disruptive behaviors� (e.g., aggression) associated with oppositional defiant disorder� or other disruptive behavioral disorders�.***For the treatment of delirium� in the pediatric intensive care unit (PICU).***For the treatment of severe behavioral or psychological symptoms of dementia�.***Formoterol***Formoterol; Mometasone | ***General Information***CNS depression, coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Agranulocytosis, hematological disease, leukopenia, neutropenia, thrombotic thrombocytopenic purpura (TTP)***Phenylketonuria***Suicidal ideation***Abrupt discontinuation***Tardive dyskinesia***Cardiac disease, cerebrovascular disease, heart failure, hypovolemia, myocardial infarction, orthostatic hypotension, syncope***Alcoholism, bradycardia, cardiac arrhythmias, coronary artery disease, females, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, QT prolongation, thyroid disease, torsade de pointes***Hyponatremia, seizure disorder, seizures***Renal failure, renal impairment***Hepatic disease***Neurological disease, Parkinson's disease***Dementia, geriatric, stroke***Dysphagia***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise***Diabetes mellitus, diabetic ketoacidosis, hypercholesterolemia, hyperglycemia, hyperlipidemia, hyperosmolar hyperglycemic state (HHS), hypertriglyceridemia, obesity***Breast cancer, hyperprolactinemia, infertility***Intravenous administration, subcutaneous administration***Priapism***Neonates, pregnancy, pregnancy testing***Breast-feeding***Children | |||||||||||||||||||||||||||||||
| 30 | ['3407'] | digoxin | ***For ventricular rate control in patients with chronic atrial fibrillation and/or atrial flutter�; or for the treatment of narrow-complex paroxysmal supraventricular tachycardia (PSVT)� or for paroxysmal supraventricular tachycardia (PSVT) prophylaxis� in patients without a delta wave on ECG during sinus rhythm; or for the treatment of congestive heart failure. <br /> NOTE: In patients with undetectable serum digoxin concentrations, the total loading dose should be based on lean body weight and clinical response, and divided into several doses administered at 4- to 8-hour intervals. Higher doses (i.e., concentrations) may be required for treating arrhythmias than for treating heart failure. Patients with moderate-severe renal insufficiency should receive smaller loading doses than patients with normal renal function due to a reduced volume of distribution.<br />NOTE: Maintenance doses should be based on lean body weight, clinical response, and renal function. Higher doses (i.e., concentrations) may be required for treating arrhythmias than for treating heart failure. Lower doses should be considered for geriatric patients, patients with impaired renal function, and in patients whose lean weight is an abnormally small fraction of their total body mass because of obesity or edema. In 1 small study of men with NYHA class II or III heart failure who were in normal sinus rhythm, left ventricular function improved significantly on a dose of 0.125 mg/day that produced mean serum concentrations of 0.8 ng/mL but doses of 0.25 mg/day and corresponding higher concentrations of 1.5 ng/mL did not produce further improvement over the lower dosage. In another small study of men with NYHA class II or III heart failure who were in normal sinus rhythm, left ventricular ejection fraction improved significantly when digoxin was increased from a mean dose of 0.2 mg/day (mean trough 0.67 ng/mL) to a mean dose of 0.39 mg/day (mean trough 1.22 ng/mL); however, no significant changes were observed in heart failure score or exercise tolerance***For the transplacental treatment of fetal supraventricular tachyarrhythmias�. | ***Acute myocardial infarction, Adams-Stokes syndrome, AV block, bradycardia, cardiomyopathy, cor pulmonale, hyperthyroidism, hypothyroidism, hypoxemia, myocarditis, myxedema, pulmonary disease, sick sinus syndrome***Carotid sinus hypersensitivity, ventricular arrhythmias, ventricular fibrillation, ventricular tachycardia, Wolff-Parkinson-White syndrome***Renal disease, renal failure, renal impairment***Geriatric***Hepatic disease***Constrictive pericarditis, idiopathic hypertrophic subaortic stenosis***Electrolyte imbalance, hypercalcemia, hyperkalemia, hypocalcemia, hypokalemia, hypomagnesemia***Hypertension***Infants, neonates, premature neonates***Pregnancy***Breast-feeding***Diarrhea, malabsorption syndrome***Intramuscular administration | |||||||||||||||||||||||||||||||
| 31 | sumatriptan succinate | ***For the acute treatment of migraine attacks with or without aura. <br /> NOTE: Sumatriptan is not indicated for hemiplegic or basilar migraine.<br /> ***For the acute treatment of cluster headache. | ***General Information***Sumatriptan hypersensitivity***Acute myocardial infarction, angina, arteriosclerosis, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, hypercholesterolemia, obesity, tobacco smoking, vasospastic angina, Wolff-Parkinson-White syndrome***Hypertension***Cerebrovascular disease, intracranial bleeding, stroke***Basilar/hemiplegic migraine***Intravenous administration***Pregnancy***Breast-feeding***Hepatic disease***Renal disease, renal failure, renal impairment***Children***Geriatric***Driving or operating machinery***Colitis, peripheral vascular disease, Raynaud's phenomenon***Seizure disorder, seizures***Visual disturbance***MAOI therapy***Magnetic resonance imaging (MRI) | ||||||||||||||||||||||||||||||||
| 32 | ['4083']['6373'] | estradiol/levonorgestrel | ***For treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae) in women with an intact uterus.***For osteoporosis prophylaxis due to menopause (either natural or surgical) in women with an intact uterus.***Formoterol; Mometasone | ***Angioedema, hereditary angioedema***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Cervical cancer, endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Cardiac disease, cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking***Surgery***Pregnancy***Breast-feeding***Gallbladder disease, hepatic disease, hepatocellular cancer, jaundice, porphyria***Systemic lupus erythematosus (SLE)***Hypertriglyceridemia, pancreatitis***Contact lenses, migraine, visual disturbance***Diabetes mellitus***Hypothyroidism, thyroid disease***Asthma, renal disease, seizure disorder***Depression***Hypocalcemia, hypoparathyroidism***Dementia, geriatric***Children, infants | |||||||||||||||||||||||||||||||
| 33 | ['1895'] | drospirenone/ethinyl estradiol/levomefolate calcium | ***For routine contraception and to increase folate levels in women who desire to use oral contraception.***For the treatment of premenstrual dysphoric disorder (PMDD) in women who desire to use an oral contraceptive.***For the treatment of moderate acne vulgaris in women who also desire to use an oral contraceptive.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, who have achieved menarche and desire contraception.***Formoterol; Mometasone | ***Adrenal insufficiency, electrolyte imbalance, hyperkalemia, renal failure, renal impairment***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, hypertension, myocardial infarction, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Breast cancer***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Surgery***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Headache, migraine***Depression***Hypothyroidism, thyroid disease***Pernicious anemia, vitamin B12 deficiency***Contact lenses, glaucoma, visual disturbance***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Obesity***Systemic lupus erythematosus (SLE)***Children, infants, neonates***Angioedema, hereditary angioedema***Chloasma | |||||||||||||||||||||||||||||||
| 34 | aminosalicylic acid | ***For the treatment of tuberculosis infection in combination with other agents as second line therapy. <br /> NOTE: Aminosalicylic acid is most commonly used in the treatment of multi-drug resistant tuberculosis or when isoniazid and rifampin therapy is not possible due to resistance and/or intolerance.<br />NOTE: The American Thoracic Society (ATS), Infectious Diseases Society of America (IDSA), and the Centers for Disease Control and Prevention (CDC) recommend short-course regimens (e.g., at least 6 months) for uncomplicated pulmonary tuberculosis and most cases of extrapulmonary tuberculosis in adults. According to the ATS, CDC, and American Academy of Pediatrics (AAP), short-course regimens are also suitable in children. The initial regimen for the treatment of tuberculosis should include four drugs unless the likelihood of INH or rifampin resistance is low (i.e., < 4%), in which case an initial regimen of INH, rifampin, and pyrazinamide may be considered. HIV positive patients should always receive induction therapy with four drugs by DOT. When drug susceptibility results are available, the regimen should be altered as appropriate. For multi-drug resistant tuberculosis (MDR-TB), drug therapy choice should be based on specific resistance patterns. For pediatrics, the CDC recommends treatment for 18�24 months after culture conversion in patients with bacteriologic confirmation and for at least 12 months in patients who are culture-negative. The World Health Organization (WHO) recommends at least 8 months of an intensive phase of treatment with a total treatment duration of 20 months in MDR-TB***For aminosalicylic acid desensitization. | ***Renal disease, renal failure***Hepatitis, jaundice***Hepatic disease***Vitamin B12 deficiency***Malabsorption syndrome***Pregnancy***Breast-feeding | ||||||||||||||||||||||||||||||||
| 35 | collagenase | ***For the treatment of severe partial- or full-thickness burns. <br /> NOTE: Removal of necrotic tissue by mechanical debridement should be considered during the initial and subsequent assessments.<br />NOTE: Collagenase should only be used on wounds that have necrotic material. Antibiotic administration is paramount for infected wounds.<br />NOTE: Collagenase should be discontinued as soon as the wound bed is devoid of necrotic tissue and has more than 90% granulation tissue***For the treatment of decubitus ulcer, diabetic foot ulcer, or varicose ulcer that requires debridement. <br /> NOTE: Removal of necrotic tissue by mechanical debridement should be considered during the initial and subsequent assessments.<br />NOTE: Collagenase should only be used on wounds that have necrotic material. Stage 1 ulcers are not appropriate candidates. Antibiotic administration is paramount for infected wounds.<br />NOTE: Collagenase should be discontinued as soon as the wound bed is devoid of necrotic tissue and has more than 90% granulation tissue***For the treatment of Dupuytren's contracture with a palpable cord.***For the treatment of Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. | ***General Information***Bone marrow suppression, hyperglycemia, immunosuppression, infection, malnutrition***Arteriosclerosis, diabetes mellitus, peripheral vascular disease***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Children***Pregnancy***Breast-feeding***Corporal rupture***Requires an experienced clinician | ||||||||||||||||||||||||||||||||
| 36 | ['8703'] | fenofibrate | ***For use as an adjunct to diet for the treatment of adult patients with severe hypertriglyceridemia. <br /> NOTE: Fenofibrate tablet and capsule formulations are not bioequivalent.<br />NOTE: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention. <br />NOTE: Markedly elevated levels of serum triglycerides (e.g., > 2000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied. ***For use as an adjunct to diet to reduce elevated LDL-cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG), and apolipoprotein B (Apo B), and to increase HDL-cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia. <br /> NOTE: Fenofibrate tablet and capsule formulations are not bioequivalent.<br />NOTE: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus. | ***General Information***Cardiac disease***Biliary cirrhosis, cholelithiasis, gallbladder disease, hepatic disease***Dialysis, renal disease, renal failure, renal impairment***Anticoagulant therapy***Thromboembolic disease***Geriatric***Children, infants, neonates***Pregnancy***Breast-feeding***Diabetes mellitus***Hypothyroidism | |||||||||||||||||||||||||||||||
| 37 | sodium oxybate | ***For the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy. | ***General Information***Succinic semialdehyde dehydrogenase deficiency***Alcoholism, behavioral changes, CNS depression, coadministration with other CNS depressants, coma, depression, driving or operating machinery, ethanol ingestion, respiratory depression, substance abuse, suicidal ideation, surgery***Hypoxemia, respiratory insufficiency, sleep apnea***Seizure disorder, seizures***Hepatic disease***Cardiac arrhythmias, cardiac disease, heart failure, hypertension, renal disease***Urinary incontinence***Electrolyte imbalance, hypernatremia, hyperprolactinemia, hypokalemia***Abrupt discontinuation***Geriatric***Eclampsia, labor, neonates, obstetric delivery, pregnancy***Breast-feeding***Children, infants | ||||||||||||||||||||||||||||||||
| 38 | ['276237'] | emtricitabine/tenofovir disoproxil fumarate | ***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents. <br /> NOTE: Emtricitabine; tenofovir disoproxil fumarate (DF) is not indicated for the treatment of chronic hepatitis B virus (HBV) infection, and safety and efficacy of treatment have not been established in patients co-infected with HBV and HIV.<br />NOTE: Children must be able to swallow whole tablets in order to use emtricitabine; tenofovir DF fixed-dose combination tablets***For human immunodeficiency virus (HIV) prophylaxis.***For HIV prophylaxis� after occupational exposure to HIV.***For pre-exposure HIV prophylaxis of uninfected individuals to reduce the risk of sexually acquired HIV-1 in adults at high risk.***For HIV prophylaxis� after nonoccupational exposure to HIV, including sexual assault. <br /> NOTE: Higher risk exposures for which prophylaxis is recommended include exposure of vagina, rectum, eye, mouth, or other mucous membrane, nonintact skin, or percutaneous contact with blood, semen, vaginal secretions, rectal secretions, breast milk, or any body fluid that is visibly contaminated with blood when the source is known to be HIV-positive. Exposures to a source patient with unknown HIV status should be assessed on a case-by-case basis.<br /***For pre-exposure HIV prophylaxis of uninfected individuals at high risk of acquiring HIV infection through injection drug use�. | ***General Information***Human immunodeficiency virus (HIV) infection resistance***Hepatitis B and HIV coinfection, hepatitis B exacerbation***Alcoholism, females, hepatic disease, hepatotoxicity or lactic acidosis, obesity***Bone fractures, hypophosphatemia, renal failure, renal impairment***Osteomalacia, osteoporosis***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Children***Pregnancy***Breast-feeding***HIV serum status***Hepatitis C and HIV coinfection | |||||||||||||||||||||||||||||||
| 39 | naratriptan hydrochloride | ***For the acute treatment of migraine with or without aura. <br /> NOTE: Naratriptan is not indicated for hemiplegic or basilar migraine.<br /> ***For menstrual migraine prophylaxis�. | ***General Information***Acute myocardial infarction, angina, arteriosclerosis, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, hypercholesterolemia, myocardial infarction, obesity, tobacco smoking, vasospastic angina, Wolff-Parkinson-White syndrome***Hypertension***Colitis, peripheral vascular disease***Cerebrovascular disease, intracranial bleeding, stroke***Basilar/hemiplegic migraine***Renal failure, renal impairment***Hepatic disease***Pregnancy***Breast-feeding***Geriatric***Driving or operating machinery | ||||||||||||||||||||||||||||||||
| 40 | ['1272'] | aztreonam | ***For the management of pulmonary infections in patients with cystic fibrosis.***For the improvement of respiratory symptoms in cystic fibrosis patients with <em>Pseudomonas aeruginosa</em> and an FEV1 between 25% to 75% predicted.***For the treatment of pulmonary exacerbation in patients with cystic fibrosis.***For the treatment of gram-negative infections including intraabdominal infections (peritonitis), gynecologic infections (endometritis, pelvic cellulitis), skin and skin structure infections (diabetic foot ulcer, postoperative wounds, burn wound infection), and bacteremia.***For the treatment of peritonitis in patients receiving peritoneal dialysis.***For the treatment of complicated and uncomplicated urinary tract infection (UTI) including cystitis and pyelonephritis.***For the treatment of lower respiratory tract infections, including bronchitis and pneumonia (community-acquired pneumonia and nosocomial pneumonia).***For the treatment of community-acquired pneumonia (CAP).***For the treatment of nosocomial pneumonia, including hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP).***For the treatment of bronchitis.***For surgical infection prophylaxis�.***For the empiric treatment of febrile neutropenia�.***For the treatment of febrile neutropenia in adults.***For the treatment of febrile neutropenia in pediatric patients. | ***General Information***Viral infection***Carbapenem hypersensitivity, cephalosporin hypersensitivity, penicillin hypersensitivity***Renal disease, renal failure, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Acute bronchospasm***Children, infants, neonates***Pregnancy***Breast-feeding***Geriatric | |||||||||||||||||||||||||||||||
| 41 | ['283810'] | bimatoprost | ***For the reduction of elevated or increased intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.***For treatment of hypotrichosis of the eyelashes. | ***General Information***Closed-angle glaucoma***Aphakia, corneal abrasion, iritis, keratitis, ocular infection, ocular surgery, ocular trauma, uveitis***Contact lenses***Sunlight (UV) exposure***Children, infants, neonates***Pregnancy***Breast-feeding | |||||||||||||||||||||||||||||||
| 42 | ['73710'] | paricalcitol | ***For the prevention and treatment of secondary hyperparathyroidism and resultant metabolic bone disease (renal osteodystrophy�). <br /> NOTE: Dosage adjustments should be determined based on serum calcium, serum phosphorous, and serum or plasma iPTH concentrations. Initially and following a dosage adjustment, serum calcium, serum phosphorous, and serum or plasma iPTH concentrations should be monitored at least every 2 weeks for 3 months, monthly for 3 months, and then every 3 months thereafter.<br /> ***For initial dosing and dosage titration in pre-dialysis patients with Stage 3 or 4 chronic kidney disease. <br /> NOTE: In general, the dose should be adjusted no more frequently than every 2 to 4 weeks in adults and every 4 weeks in pediatric patients. In clinical trials of paricalcitol in adults, the average weekly dose was 9.6 mcg in patients taking once daily and 9.5 mcg in patients taking 3 times per week.<br /***For initial dosing and dosage titration in patients with Stage 5 chronic kidney disease on dialysis.***For initial dosing and dosage titration in patients with stage 5 chronic kidney disease on dialysis (National Kidney Foundation Guidelines). <br /> NOTE: Serum calcium concentration should be less than 9.5 mg/dL in patients with a serum iPTH less than 1000 pg/mL. In patients with a serum iPTH greater 1000 pg/mL, the serum calcium concentration should be less than 10 mg/dL. Serum phosphorous concentration should be less than 5.5 mg/dL and the calcium-phosphorous product should be less than 55.<br />Dosage adjustments should be determined based on serum calcium, serum phosphorous, and plasma iPTH concentrations. Initially and during dosage titration, monitor serum calcium and phosphorous concentrations every 2 weeks for 1 month and then monthly. Plasma iPTH concentration should be monitored monthly for 3 months then every 3 months once target iPTH concentrations are achieved (150 to 300 pg/mL) | ***Hypercalcemia***Hypervitaminosis D***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric | |||||||||||||||||||||||||||||||
| 43 | hepatitis B vaccine (recombinant) | ***For hepatitis B prophylaxis.***For prophylaxis of hepatitis B using Recombivax HB.***For prophylaxis of hepatitis B using Engerix-B.***For booster vaccination using Engerix-B.***For prophylaxis of hepatitis B using Heplisav-B. | ***General Information***Yeast hypersensitivity***Neonates, premature neonates***Anticoagulant therapy, coagulopathy, hemophilia, intravenous administration, subcutaneous administration, thrombocytopenia, vitamin K deficiency***Cardiac disease, fever, infection***Chemotherapy, human immunodeficiency virus (HIV) infection, immunosuppression***Dialysis, renal disease, renal failure***Pregnancy***Breast-feeding***Latex hypersensitivity | ||||||||||||||||||||||||||||||||
| 44 | leuprolide acetate | ***For the palliative treatment of advanced prostate cancer, particularly when orchiectomy or estrogen therapy are not indicated or are unacceptable.***For the management of endometriosis including pain relief and reduction of endometriotic lesions.***For the treatment of central precocious puberty (idiopathic or neurogenic) in children. <br /> NOTE: Leuprolide has been designated an orphan drug by the FDA for this indication.<br />NOTE: Downregulation is determined by GnRH agonist stimulation test, sex steroid concentrations, and Tanner staging. Give consideration to discontinuing treatment before 11 years of age in girls and 12 years of age in boys***For the preoperative treatment of anemia due to uterine leiomyomata (fibroids) in combination with iron supplementation when iron therapy alone fails to correct the anemia.***For the treatment of benign prostatic hyperplasia (BPH)�.***For the adjuvant treatment of premenopausal women with hormone receptor-positive breast cancer�.***For the treatment of nonspecific symptoms associated with premenstrual syndrome (PMS)�.***For inhibiting premature leuteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation and subsequent in vitro fertilization (IVF) or other assisted reproductive technology (ART) for the treatment of infertility�. <br /> NOTE: Drugs such as ganirelix and cetrorelix are now more commonly used and are FDA-approved for this purpose. Leuprolide should only be used by a qualified infertility specialist. Withhold HCG administration in cases where the ovaries are abnormally enlarged to reduce the chance of inducing ovarian hyperstimulation syndrome (OHSS).<br /> ***For prevention of stuttering priapism� (i.e., recurrent priapism).***Formoterol***Formoterol; Mometasone | ***Benzyl alcohol hypersensitivity***Gonadotropin-Releasing Hormone (GnRH) analogs hypersensitivity***Renal impairment, spinal cord compression, urinary tract obstruction***Pituitary insufficiency***Dysfunctional uterine bleeding, menstruation, vaginal bleeding***Children, geriatric, osteoporosis***Females, pregnancy***Breast-feeding***Cardiac disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, stroke, tobacco smoking***Diabetes mellitus, hyperglycemia***Alcoholism, cardiac arrhythmias, coronary artery disease, heart failure, hepatic disease, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, QT prolongation, thyroid disease***Brain tumor, cerebrovascular disease, seizure disorder***Depression, suicidal ideation | ||||||||||||||||||||||||||||||||
| 45 | ['228790']['77492'] | dutasteride/tamsulosin hydrochloride | ***For the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate. <br /> NOTE: Instruct patient to swallow capsules whole; do not chew or open since contact with the capsule contents may cause irritation of the oropharyngeal mucosa.<br /> | ***General Information***Females, pregnancy***Breast-feeding***Children, infants, neonates***Geriatric, orthostatic hypotension, renal disease, renal failure, renal impairment, syncope***Prostate cancer, urinary tract obstruction***Blood donation***Ocular surgery***Sulfonamide hypersensitivity***Hepatic disease***Priapism***Infertility | |||||||||||||||||||||||||||||||
| 46 | loteprednol etabonate/tobramycin | ***For the treatment of corticosteroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where a superficial bacterial ophthalmic infection or a risk of bacterial infection exists, including bacterial conjunctivitis, allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster ocular infection (keratitis), iritis, cyclitis, and chronic anterior uveitis or corneal injury resulting from chemical, radiation, or thermal ocular burns or from the penetration of foreign bodies. <br /> NOTE: Care should be taken not to discontinue therapy prematurely. Not more than 20 mL should be prescribed initially and the prescription should not be refilled without further evaluation.<br / | ***Aminoglycoside hypersensitivity, corticosteroid hypersensitivity, glycerin hypersensitivity***Fungal infection, herpes infection, herpes simplex keratitis (dendritic keratitis), mycobacterial infection, ocular infection, varicella, viral infection***Glaucoma, increased intraocular pressure, open-angle glaucoma***Cataracts***Diabetes mellitus***Corneal abrasion***Contact lenses***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric | ||||||||||||||||||||||||||||||||
| 47 | ['38454']['11170'] | trandolapril/verapamil hydrochloride | ***For the treatment of hypertension in patients who do not respond to monotherapy. <br /> NOTE: Individualize the dosage by titration of the separate components. If the optimal dose corresponds to the ratio contained in the combination formulation, this product can be used for convenient dosing.<br />NOTE: The possibility of exacerbation of hypotensive effects with trandolapril; verapamil in patients taking diuretics may be minimized by either discontinuing the diuretic or cautiously increasing the salt intake prior to initiating this combination. If it is not possible to discontinue the diuretic, the starting dose should be reduced | ***ACE-inhibitor induced angioedema, angioedema, Angiotensin-converting enzyme inhibitors (ACE inhibitors) hypersensitivity, Black patients, hereditary angioedema***Acute myocardial infarction, bradycardia, cardiogenic shock, heart failure, ventricular dysfunction***AV block, sick sinus syndrome***Atrial fibrillation, atrial flutter, Lown-Ganong-Levine syndrome, ventricular tachycardia, Wolff-Parkinson-White syndrome***Myasthenia gravis, neuromuscular disease***Constipation, fecal impaction, GI obstruction, ileus***Diabetes mellitus, hyperkalemia***Autoimmune disease, bone marrow suppression, collagen-vascular disease, immunosuppression, renal artery stenosis, renal disease, renal failure, renal impairment, scleroderma, systemic lupus erythematosus (SLE)***Aortic stenosis, cardiomyopathy, cerebrovascular disease, coronary artery disease, dialysis, hyponatremia, hypotension, hypovolemia***Hymenoptera venom (insect sting) allergy desensitization, low-density lipoprotein apheresis***Geriatric***Hepatic disease***Surgery***Pregnancy***Breast-feeding***Children | |||||||||||||||||||||||||||||||
| 48 | ['614391'] | abatacept | ***For the treatment of moderate to severe rheumatoid arthritis to reduce signs and symptoms of the disease, to induce a major clinical response, to inhibit the progression of structural damage, and to improve physical function.***For the treatment of moderate to severe polyarticular juvenile idiopathic arthritis as monotherapy or with methotrexate to reduce signs and symptoms of the disease.***For the treatment active psoriatic arthritis in adult patients. | ***Maltose hypersensitivity***Agranulocytosis, asthma, bone marrow suppression, chronic obstructive pulmonary disease (COPD), corticosteroid therapy, cystic fibrosis, diabetes mellitus, emphysema, hepatitis, immunosuppression, infection, respiratory infection, sepsis, tobacco smoking, tuberculosis***Neoplastic disease***Geriatric***Children, infants***Pregnancy***Breast-feeding***Hyperglycemia***Vaccination | |||||||||||||||||||||||||||||||
| 49 | ['31555'] | nebivolol | ***For the treatment of hypertension either alone or in combination with other agents.***For the treatment of heart failure�.***For migraine prophylaxis�. | ***General Information***Abrupt discontinuation, coronary artery disease***Acute heart failure, AV block, bradycardia, cardiogenic shock, sick sinus syndrome***Hepatic disease***Acute bronchospasm***Hyperthyroidism, thyrotoxicosis***Diabetes mellitus***Surgery***Peripheral vascular disease***Pheochromocytoma***Renal impairment***Geriatric***Children, infants, neonates***Pregnancy***Breast-feeding | |||||||||||||||||||||||||||||||
| 50 | acetylcholine chloride | ***For miosis induction in cataract surgery, in penetrating keratoplasty, iridectomy and other anterior segment ocular surgery where rapid miosis may be required. | ***General Information***Iritis***Children, infants, neonates***Pregnancy***Breast-feeding | ||||||||||||||||||||||||||||||||
| 51 | eprosartan mesylate/hydrochlorothiazide | ***For the treatment of hypertension in patients who do not respond to monotherapy. <br /> NOTE: Individualize the dosage by titration of the separate components. If the optimal dose corresponds to the ratio contained in the combination formulation, this product can be used for convenient dosing.<br /> ***Formoterol***Formoterol; Mometasone | ***General Information***Asthma, penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Anuria, heart failure, renal artery stenosis, renal disease, renal failure, renal impairment***Hepatic disease***Hypotension, hypovolemia, orthostatic hypotension, sympathectomy, syncope***ACE-inhibitor induced angioedema, angioedema***Surgery***Pregnancy***Breast-feeding***Children***Electrolyte imbalance, hypercalcemia, hyperkalemia, hypokalemia, hypomagnesemia, hyponatremia***Diabetes mellitus, hyperglycemia***Pancreatitis***Gout, hyperuricemia***Systemic lupus erythematosus (SLE)***Sunlight (UV) exposure***Geriatric | ||||||||||||||||||||||||||||||||
| 52 | olopatadine hydrochloride | ***For the treatment of the signs and symptoms of allergic conjunctivitis, including ocular pruritus.***For the treatment of symptoms associated with seasonal allergic rhinitis such as rhinorrhea, sneezing, and nasal pruritus. | ***Contact lenses***Geriatric***Driving or operating machinery***Children, infants, neonates***Nasal septal perforation, nasal trauma***Depression***Pregnancy***Breast-feeding | ||||||||||||||||||||||||||||||||
| 53 | ['1092437'] | belimumab | ***For the treatment of active, autoantibody-positive, systemic lupus erythematosus (SLE) in combination with standard therapy. | ***Infusion-related reactions, requires an experienced clinician, risk of serious hypersensitivity reactions or anaphylaxis***Immunosuppression, infection, progressive multifocal leukoencephalopathy***Depression, psychiatric event, suicidal ideation***Vaccination***New primary malignancy***Black patients***Infants, neonates, pregnancy***Contraception requirements, reproductive risk***Breast-feeding***Geriatric***Children | |||||||||||||||||||||||||||||||
| 54 | ['6373'] | levonorgestrel | ***For routine contraception.***For use as postcoital contraception within 72 hours of unprotected intercourse or known or suspected contraceptive failure - for use in females who have no known contraindications to use, have achieved menarche, and are not known or suspected to be pregnant.***For the treatment of menorrhagia (heavy menstrual bleeding).***For the treatment of endometriosis� in females with no contraindications to hormonal contraceptives, who have achieved menarche and desire contraception. | ***General Information***Ectopic pregnancy, intrauterine fetal death, pregnancy, pregnancy testing***Breast-feeding***Cervical cancer, incomplete abortion, uterine cancer, vaginal bleeding***Breast cancer***Menstrual irregularity, ovarian cyst***Diabetes mellitus***Children***Hepatic disease, hepatocellular cancer, jaundice***Asian patients***Obstetric delivery***Requires an experienced clinician, uterine leiomyomata***Acquired immunodeficiency syndrome (AIDS), cervicitis, endometritis, infection, leukemia, vaginal discharge, vaginitis***Human immunodeficiency virus (HIV) infection, sexually transmitted disease***Bradycardia, seizure disorder, syncope***Obesity***Anticoagulant therapy, coagulopathy***Cerebrovascular disease, hypertension, myocardial infarction, stroke, thromboembolic disease, thrombophlebitis, tobacco smoking, valvular heart disease***Headache, migraine, visual disturbance***Renal disease***Magnetic resonance imaging (MRI) | |||||||||||||||||||||||||||||||
| 55 | rabeprazole sodium | ***For the symptomatic treatment of non-erosive gastroesophageal reflux disease (GERD).***For the healing of duodenal ulcer. <br /> NOTE: For dosing in patients with gastric or duodenal ulcers due to H. pylori, see �H. pylori eradication� indication.<br /> ***For the treatment of erosive esophagitis (erosive GERD).***For the treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome.***For the short-term treatment of frequent dyspepsia� or pyrosis (heartburn)� that occurs >= 2 times per week.***For the healing of gastric ulcer�. <br /> NOTE: For dosing in patients with gastric or duodenal ulcers due to H. pylori, see �H. pylori eradication� indication.<br /> ***For the treatment of proton-pump inhibitor-responsive esophageal eosinophilia (PPI-REE) in the differential diagnosis of eosinophilic esophagitis (EoE)�. | ***Proton pump inhibitors (PPIs) hypersensitivity***Hepatic disease***Diarrhea, pseudomembranous colitis***Gastric cancer***Vitamin B12 deficiency***Bone fractures, geriatric, osteoporosis***Hypomagnesemia, long QT syndrome***Rebound acid hypersecretion***Pregnancy***Breast-feeding***Infants, neonates***Systemic lupus erythematosus (SLE)***Laboratory test interference | ||||||||||||||||||||||||||||||||
| 56 | onabotulinumtoxinA | ***For the treatment of blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders.***For the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia.***For the treatment of strabismus. <br /> NOTE: Injection should be carried out only with electromyographic guidance. The toxin must be suitably diluted, and the volume injected should be between 0.05�0.15 mL per muscle, dependent on the extent of strabismus. Use the lower doses for small deviations and the larger doses only for large deviations. Initial doses typically create paralysis of injected muscles beginning 1�2 days after injection and increasing in intensity during the first week. The paralysis lasts for 2�6 weeks and gradually resolves over a similar time period. Overcorrections lasting longer than 6 months rarely occur. About 50% of patients will require subsequent doses because of inadequate paralytic response to the initial dose, because of mechanical factors such as large deviations or restrictions, or because of the lack of binocular motor fusion to stabilize the alignment.<br /***For vertical muscles, and for horizontal strabismus of less than 20 prism diopters.***For horizontal strabismus of 20 prism diopters to 50 prism diopters.***For persistent VI nerve palsy of 1 month or longer duration.***For subsequent dosing for residual or recurrent strabismus.***For temporary improvement in the appearance of facial wrinkles.***For temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugators and/or procerus muscle activity.***For temporary improvement in the appearance of other wrinkles such as melolabial folds� and other hyperkinetic facial lines�.***For temporary improvement in the appearance of moderate to severe lateral canthal lines associated with orbicularis oculi activity (crow's feet).***For the treatment of moderate to severe forehead lines associated with frontalis muscle activity.***For the treatment of spasticity.***For the chronic management of focal spasticity� in pediatric patients with cerebral palsy with concurrent equinus gait (tiptoeing).***For the treatment of severe primary axillary hyperhidrosis (excessive underarm sweating). <br /> NOTE: Safety and efficacy for the treatment of hyperhidrosis in other body areas have not ben established. Use for palmar hyperhidrosis may lead to weakness of hand muscles and use for facial hyperhidrosis may lead to blepharoptosis.<br />NOTE: Evaluate patients for potential causes of secondary hyperhidrosis (e.g. hyperthyroidism) prior to initiating therapy***For migraine prophylaxis in adult patients with chronic migraine.***For the treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition (e.g., as occurs with neurogenic bladder in spinal cord injury, multiple sclerosis) in patients with an inadequate response or intolerance to an anticholinergic medication.***For second line treatment of neurogenic bladder� in children.***For the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency in adults intolerant to or with inadequate response from anticholinergic medications.***For the treatment of achalasia�.***For the treatment of sialorrhea� (excessive drooling).***For sialorrhea� associated with Parkinson's disease�.***For sialorrhea� associated with amyotrophic lateral sclerosis (ALS)�.***For sialorrhea� associated with cerebral palsy� . | ***General Information***Intravenous administration, requires an experienced clinician***Cerebral palsy, children, distant spread of toxin effects, infants, neonates***Infection, urinary tract infection (UTI)***Hyperthyroidism, thyroid disease***Albumin hypersensitivity, viral infection***Dysphagia***Pregnancy***Breast-feeding***Geriatric***Ocular disease, visual disturbance***Amyotrophic lateral sclerosis (ALS), autonomic neuropathy, myasthenia gravis, myopathy, neuromuscular disease***Cardiac disease***Respiratory insufficiency***Driving or operating machinery***Surgery***Anticoagulant therapy***Urinary retention | ||||||||||||||||||||||||||||||||
| 57 | methylphenidate hydrochloride | ***For the treatment of attention-deficit hyperactivity disorder (ADHD).***For once-daily product dosing.***For the treatment of narcolepsy.***For the treatment of major depression� or post-stroke depression refractory to other therapies. <br /> NOTE: The use of stimulants for the treatment of depressive disorders is usually limited to treatment-refractory cases or when standard medical therapies are not tolerated. Stimulants may aggravate coexisting anxiety or agitation in depressed patients.<br /> | ***General Information***Hereditary fructose intolerance***Anxiety, bipolar disorder, depression, mania, psychosis, schizophrenia, suicidal ideation***Tics, Tourette's syndrome***Glaucoma, visual disturbance***Abrupt discontinuation, alcoholism, substance abuse***Hypertension***Acute myocardial infarction, aortic stenosis, arteriosclerosis, cardiac arrhythmias, cardiac disease, cardiomyopathy, congenital heart disease, coronary artery disease, heart failure, myocardial infarction, prosthetic heart valves, valvular heart disease, ventricular arrhythmias, ventricular dysfunction***Cerebrovascular disease, stroke***Children, growth inhibition***Hyperthyroidism***Seizure disorder, seizures***Neonates, pregnancy***Breast-feeding***Driving or operating machinery***Surgery***Radiographic contrast administration***Dysphagia, esophageal stricture, GI obstruction, ileus***Hepatic disease***Geriatric***MAOI therapy***Peripheral vascular disease, Raynaud's phenomenon***Chemical leukoderma, skin hypopigmentation, vitiligo***Phenylketonuria | ||||||||||||||||||||||||||||||||
| 58 | ['228790'] | dutasteride | ***For the treatment of benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve urinary symptoms, reduce risk of acute urinary retention, and reduce the risk of the need for BPH-related surgery. <br /> NOTE: Instruct patient to swallow capsules whole; do not chew or open since contact with the capsule contents may cause irritation of the oropharyngeal mucosa.<br /> ***For use in combination with tamsulosin.***For the treatment of male pattern hair loss� (i.e., androgenetic alopecia�), in patients with mild to moderate hair loss of the vertex and anterior mid-scalp area. | ***General Information***Females, pregnancy***Breast-feeding***Hepatic disease***Children, infants, neonates***Prostate cancer, urinary tract obstruction***Blood donation***Infertility | |||||||||||||||||||||||||||||||
| 59 | ['57308'] | topotecan | ***For the treatment of patients with metastatic ovarian cancer with disease progression on or after initial or subsequent chemotherapy. <br /> NOTE: Patients must have a neutrophil count > 1500 cells/mm3 and a platelet count > 100,000 cells/mm3 before topotecan initiation. Do NOT give subsequent courses of topotecan until the neutrophil count is > 1000 cells/mm3, the platelet count is > 100,000 cells/mm3, and the hemoglobin concentration is > 9 g/dL (transfusion may be necessary).<br /***For the treatment of small cell lung cancer (SCLC). <br /> NOTE: Patients must have a neutrophil count > 1500 cells/mm3 and a platelet count > 100,000 cells/mm3 before topotecan initiation. Do NOT give subsequent courses of topotecan until the neutrophil count is > 1000 cells/mm3, the platelet count is > 100,000 cells/mm3, and the hemoglobin concentration is > 9 g/dL (transfusion may be necessary).<br /> ***For platinum-sensitive small cell lung cancer (SCLC) who progressed at least 60 days after initiation of first-line chemotherapy.***For relapsed small cell lung cancer (SCLC) in patients with a prior complete or partial response and who are at least 45 days from the end of first-line chemotherapy.***For chemotherapy-naive, extensive-stage SCLC in combination with paclitaxel�.***For chemotherapy-naive, extensive-stage SCLC sequentially after treatment with cisplatin and etoposide�.***For the treatment of stage IV-B recurrent or persistent cervical cancer that is not amendable to curative treatment with surgery and/or radiation therapy. <br /> NOTE: Patients must have a neutrophil count > 1500 cells/mm3 and a platelet count > 100,000 cells/mm3 before topotecan initiation. Do NOT give subsequent courses of topotecan until the neutrophil count is > 1000 cells/mm3, the platelet count is > 100,000 cells/mm3, and the hemoglobin concentration is > 9 g/dL (transfusion may be necessary).<br /> ***For the treatment of metastatic rhabdomyosarcoma� in combination with cyclophosphamide and vincristine alternating with VAC.***For the treatment of non-small cell lung cancer (NSCLC)�.***For the treatment of previously untreated advanced non-small cell lung cancer (NSCLC) in combination with gemcitabine�.***For the second-line treatment of advanced non-small cell lung cancer in combination with gemcitabine�. | ***Gelatin hypersensitivity, mannitol hypersensitivity***Anemia, bone marrow suppression, herpes infection, infection, neutropenia, radiation therapy, thrombocytopenia, varicella, viral infection***Dehydration, diarrhea***Lung cancer, pulmonary fibrosis***Extravasation***Children, infants, neonates***Pregnancy***Contraception requirements, infertility, male-mediated teratogenicity, reproductive risk***Breast-feeding | |||||||||||||||||||||||||||||||
| 60 | ['4678'] | ganciclovir | ***For induction treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including HIV-infected patients.***For cytomegalovirus (CMV) disease prophylaxis in patients at risk for CMV disease.***For prophylaxis in allogeneic hematopoietic cell transplant (HCT) recipients.***For solid organ transplant recipients who are CMV-seropositive or CMV-seronegative receiving an organ from a CMV-seropositive donor. <br /> NOTE: Treatment regimens are organ, transplant center, and recipient specific; CMV hyperimmune globulin may be added to the ganciclovir regimen and/or the duration of IV therapy may vary from 14 days to 6 months, with total ganciclovir treatment duration of 3 to 6 months.<br /> ***For solid organ transplant recipients who are CMV-seropositive and receiving immunosuppressive induction therapy (i.e., transplant rejection treatment) with antithymocyte globulin (ATG)�.***For preemptive therapy in hematopoietic cell transplant (HCT) recipients who are less than 100 days post HCT�.***For preemptive therapy in hematopoietic cell transplant (HCT) recipients who are more than 100 days post HCT�.***For the treatment of acute herpes simplex keratitis (dendritic keratitis). <br /> NOTE: Ganciclovir ophthalmic gel is an FDA-designated orphan drug for this indication.<br /> ***For chronic suppressive therapy of cytomegalovirus (CMV) disease, including CMV retinitis (i.e., secondary cytomegalovirus (CMV) retinitis prophylaxis) in HIV-infected patients. <br /> NOTE: Ganciclovir intravenous injection has been designated an orphan drug by the FDA for CMV retinitis.<br />NOTE: The HIV guidelines generally do not recommend ganciclovir for chronic suppressive therapy following acute CMV disease other than retinitis in adults and adolescents. In infants and children, chronic suppressive therapy is recommended after disseminated disease, neurologic disease, retinitis, or gastrointestinal disease with relapse.<br />NOTE: For patients who experience progression of CMV retinitis while receiving maintenance therapy, re-induction treatment with the same drug used for maintenance followed by reinstitution of maintenance therapy is recommended.***For the treatment of viral encephalitis�.***For varicella-zoster (herpes zoster) encephalitis� as an alternative to acyclovir.***For the treatment of cytomegalovirus (CMV) encephalitis� and for the treatment of cytomegalovirus (CMV) neurological disease� (including encephalitis�) in HIV-infected patients.***For encephalitis� due to B virus (cercopithecine herpesvirus) infection� as an alternative to valacyclovir.***For the treatment of cytomegalovirus (CMV)-associated gastrointestinal disease� (e.g., esophagitis�, gastroenteritis�, or colitis�).***For the treatment of cytomegalovirus (CMV) pneumonitis�.***For the treatment of symptomatic congenital cytomegalovirus (CMV) disease�.***For the treatment of acute retinal necrosis (ARN)� due to varicella-zoster virus in HIV-infected patients.***For the treatment of progressive outer retinal necrosis (PORN)� due to varicella zoster virus (VZV)� in HIV-infected patients.***For the treatment of severe human herpesvirus 8 (HHV-8) infection� and associated diseases in HIV-infected patients, including multicentric Castleman disease� (MCD) and primary effusion lymphoma� (PEL).***For multicentric Castleman disease (MCD)�.***For the treatment of herpes simplex virus infection� or varicella (chickenpox) infection� due to varicella-zoster virus in hospitalized immunocompromised patients unable to take oral therapy. <br /> NOTE: For CNS disease, see encephalitis.<br /> ***For the treatment of neonatal herpes simplex virus infection�.***For the treatment of encephalitis caused by human herpesvirus 6 (HHV-6) infection� in immunocompromised patients. | ***Acyclovir hypersensitivity, famciclovir hypersensitivity, ganciclovir hypersensitivity, penciclovir hypersensitivity, valacyclovir hypersensitivity, valganciclovir hypersensitivity***Anemia, bone marrow suppression, chemotherapy, leukopenia, neutropenia, radiation therapy, thrombocytopenia***Intramuscular administration, subcutaneous administration***Dehydration, geriatric, renal failure, renal impairment***Accidental exposure, neoplastic disease, ocular exposure***Children, infants, neonates***Infertility, reproductive risk***Antimicrobial resistance***Contraception requirements, male-mediated teratogenicity, pregnancy, pregnancy testing***Breast-feeding***Contact lenses | |||||||||||||||||||||||||||||||
| 61 | glucagon (rDNA origin) | ***For the treatment of severe hypoglycemia.***For the treatment of severe hypoglycemia in neonates.***For use in radiographic examination of the GI tract.***For the treatment of congenital hyperinsulinemia� (e.g., hyperinsulinemic hypoglycemia).***For the treatment of beta-blocker toxicity�, or for adjunctive treatment of calcium channel blocker toxicity (e.g., verapamil toxicity�).***For the emergency treatment of choking due to esophageal foreign body impaction�. | ***General Information***Insulinoma, pheochromocytoma***Adrenal insufficiency, malnutrition***Cardiac disease, coronary artery disease***Children***Pregnancy***Breast-feeding | ||||||||||||||||||||||||||||||||
| 62 | acyclovir | ***For the treatment of neonatal herpes simplex virus infection.***For the treatment of viral encephalitis.***For herpes simplex encephalitis.***For varicella-zoster encephalitis�.***For encephalitis due to B virus (cercopithecine herpesvirus) infection� as an alternative to valacyclovir.***For the treatment of herpes labialis (i.e., cold sores) or herpes fibrilis caused by herpes simplex virus.***For the treatment of recurrent herpes labialis in immunocompetent adults.***For the treatment of varicella (chickenpox) infection.***For the treatment of varicella (chickenpox) infection in immunocompetent patients.***For the treatment of for varicella (chickenpox) infection in immunocompromised patients.***For the treatment of herpes zoster (shingles) infection. <br /> NOTE: For CNS infections, see encephalitis.<br /> ***For the treatment of herpes zoster (shingles) infection in bone marrow and organ transplant patients, patients receiving chemotherapy, and other immunocompromised patients.***For the treatment of herpes zoster (shingles) infection in immunocompetent patients.***For the treatment of herpes genitalis caused by herpes simplex virus.***For the treatment of initial herpes genitalis infection.***For the treatment of recurrent herpes genitalis.***For chronic suppression therapy of recurrent herpes genitalis (i.e., herpes genitalis prophylaxis).***For the treatment of complicated herpes simplex virus infection (e.g., disseminated disease�, pneumonitis�, infection in immunocompromised hosts, and infections requiring hospitalization). <br /> NOTE: For congenital herpes, see neonatal herpes simplex virus infection; for CNS disease, see encephalitis.<br /> ***For neonatal herpes simplex virus infection prophylaxis� (i.e., suppressive therapy) in neonates with any neonatal herpes simplex disease classification.***For chronic suppression of recurrent herpes labialis� (i.e., herpes labialis prophylaxis�).***For herpes simplex infection prophylaxis� in immunocompromised hosts.***For primary herpes simplex infection prophylaxis in HSV-seropositive recipients of a bone marrow transplant�.***For primary herpes simplex infection prophylaxis in immunocompromised hosts who are HSV-seropositive patients�.***For primary varicella (chickenpox) infection prophylaxis� in HIV-infected patients with significant exposure to chickenpox or shingles for patients who have no history of either condition or, if available, negative antibody to varicella-zoster virus (VZV).***For cytomegalovirus (CMV) disease prophylaxis�.***For prevention of CMV disease� in immunocompromised patients.***For prevention of CMV disease� in CMV-seropositive patients receiving bone marrow transplantation.***For CMV disease prophylaxis� in adults receiving renal transplantation.***For the treatment of hairy leukoplakia� in HIV-positive adults.***For the adjunctive treatment of Bell's palsy�in combination with steroids.***For secondary herpes simplex ocular infection prophylaxis�.***For the treatment of acute herpes zoster ocular infection� (herpes zoster ophthalmicus�) in immunocompetent patients.***For the treatment of acute retinal necrosis (ARN)� due to varicella-zoster virus in HIV-infected patients. | ***Acyclovir hypersensitivity, famciclovir hypersensitivity, ganciclovir hypersensitivity, milk protein hypersensitivity, penciclovir hypersensitivity, valacyclovir hypersensitivity, valganciclovir hypersensitivity***Dehydration, renal failure, renal impairment***Neurological disease, seizure disorder***Geriatric***Pregnancy***Breast-feeding***Children, infants, neonates***Ophthalmic administration***Extravasation, intramuscular administration, subcutaneous administration***Obesity | ||||||||||||||||||||||||||||||||
| 63 | ['5487']['10763'] | hydrochlorothiazide/triamterene | ***For the treatment of peripheral edema or hypertension. <br /> NOTE: Determine dosage by individual titration of the separate components. When triamterene is administered with other diuretics, it is recommended that the initial dosage of each drug be lowered and then adjusted to attain clinical goals.<br />NOTE: Diuretics do not prevent the development of edema associated with toxemia of pregnancy, and should be avoided to minimize unnecessary risk to the mother and fetus***Formoterol***Formoterol; Mometasone | ***General Information***Asthma, penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Anuria, diabetes mellitus, electrolyte imbalance, geriatric, hyperglycemia, hyperkalemia, hypovolemia, renal disease, renal failure, renal impairment***Hypotension, orthostatic hypotension, sympathectomy, syncope***Hypercalcemia, hyponatremia***Acid/base imbalance, metabolic acidosis, respiratory acidosis***Pancreatitis***Preeclampsia, pregnancy***Breast-feeding***Children, infants, neonates***Hepatic disease, jaundice***Gout, hyperuricemia, nephrolithiasis***Systemic lupus erythematosus (SLE)***Sunlight (UV) exposure | |||||||||||||||||||||||||||||||
| 64 | ['195088']['85762'] | lopinavir/ritonavir | ***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents. <br />NOTE: The following abbreviations are used: nucleoside reverse transcriptase inhibitors (NRTIs); nonnucleoside reverse transcriptase inhibitors (NNRTIs); protease inhibitors (PIs).<br />NOTE: Lopinavir; ritonavir should not be administered once daily in pediatric patients due to inferior efficacy observed with once daily dosing compared with twice daily dosing.<br /***For human immunodeficiency virus (HIV) prophylaxis�.***For human immunodeficiency virus (HIV) prophylaxis� after occupational exposure.***For human immunodeficiency virus (HIV) prophylaxis� after nonoccupational exposure, including sexual assault.***Formoterol***Formoterol; Mometasone | ***General Information***Hepatitis, hepatitis B and HIV coinfection***Alcoholism, hepatic disease, jaundice***Hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, pancreatitis***Diabetes mellitus, diabetic ketoacidosis, hyperglycemia***Hemophilia***Human immunodeficiency virus (HIV) infection resistance***Children, infants, neonates***Breast-feeding***Pregnancy***AV block, cardiac disease, cardiomyopathy***Bradycardia, cardiac arrhythmias, coronary artery disease, females, geriatric, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Hepatitis C and HIV coinfection | |||||||||||||||||||||||||||||||
| 65 | penicillin G benzathine | ***For the treatment of yaws (<em>Treponema pallidum</em> subsp. pertenue), pinta (<em>Treponema carateum</em>), and bejel (<em>Treponema pallidum</em> subsp. endemicum).***For the treatment of upper respiratory tract infections such as pharyngitis, including group A beta-hemolytic streptococcal (GAS) pharyngitis (rheumatic fever prophylaxis), and for bacterial colonization eradication� in chronic carriers of group A beta-hemolytic <em>Streptococci</em> (GAS)�.***For secondary prevention of rheumatic fever (prevention of recurrent rheumatic fever attacks) or poststreptococcal glomerulonephritis.***For the treatment of chronic carriers of group A beta-hemolytic <em>Streptococci</em> (GAS)� (bacterial colonization eradication).***For diphtheria prophylaxis�.***For the treatment of syphilis (<em>Treponema pallidum</em>), including neurosyphilis�. <br /> NOTE: Pregnant women with syphilis in any stage who report with penicillin allergy should be desensitized and treated with penicillin.<br />NOTE: The Jarisch-Herxheimer reaction may occur within the first 24 hours of therapy***For the treatment of primary, secondary, or early latent (less than 1 year duration) syphilis.***For the treatment of late latent (greater than 1 year duration) syphilis or latent syphilis of unknown duration.***For the treatment of late or tertiary syphilis (patients with gumma and cardiovascular syphilis). <br /> NOTE: The CDC recommends ruling out neurosyphilis prior to treatment.<br /> ***For the follow up treatment of neurosyphilis�. <br /> NOTE: Benzathine penicillin is NOT indicated for treatment of neurosyphilis but only as follow-up after therapy with aqueous penicillin G. Aqueous penicillin G injection is recommended. However, optimum treatment schedules for neurosyphilis have not been established. The dosage regimens recommended for neurosyphilis are shorter than the regimen used for late syphilis in the absence of neurosyphilis.<br /> ***For the treatment of congenital syphilis (<em>Treponema pallidum</em>). <br /> NOTE: Current CDC guidelines should be consulted to determine the appropriate course of treatment in neonates born to mothers with syphilis. Therapy is based on physical examination, serum quantitive nontreponemal serologic titer, and whether or not the mother was treated properly before delivery. <br /> | ***Viral infection***Asthma, carbapenem hypersensitivity, cephalosporin hypersensitivity, penicillin hypersensitivity***Intravenous administration***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Renal failure, renal impairment***Pregnancy***Breast-feeding***Geriatric***Infants, neonates | ||||||||||||||||||||||||||||||||
| 66 | ['714438'] | pazopanib | ***For the treatment of advanced renal cell cancer.***For the treatment of advanced soft-tissue sarcoma in patients who have received prior chemotherapy. <br /> NOTE: Efficacy of pazopanib for the treatment of adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated.<br /> ***For the treatment of unresectable, locally advanced, or metastatic gastrointestinal stromal tumors (GIST), after progression on or intolerance to both imatinib and sunitinib�. | ***General Information***Geriatric, hepatic disease, hepatotoxicity***Angina, myocardial infarction, stroke***Heart failure, hypertension***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, QT prolongation, thyroid disease***Bleeding, GI bleeding, intracranial bleeding***Hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura (TTP)***Surgery, wound dehiscence***Hypothyroidism***Proteinuria***Children, infants, neonates***Asian patients, neutropenia, serious rash, thrombocytopenia***Pregnancy***Pneumonitis***Contraception requirements, infertility, male-mediated teratogenicity, pregnancy testing, reproductive risk***Breast-feeding | |||||||||||||||||||||||||||||||
| 67 | ['22968']['4083'] | dienogest/estradiol valerate | ***For routine contraception.***For the treatment of menorrhagia (heavy and/or prolonged menstrual bleeding) in females who also desire contraception.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, who have achieved menarche and desire contraception.***Formoterol; Mometasone | ***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Pregnancy***Breast-feeding, obstetric delivery***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia, pancreatitis***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, hypertension, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Surgery***Headache, migraine***Depression***Children, infants, neonates***Breast cancer***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Geriatric***Angioedema, hereditary angioedema***Systemic lupus erythematosus (SLE)***Chloasma***Contact lenses, glaucoma, visual disturbance | |||||||||||||||||||||||||||||||
| 68 | ['337523'] | ixabepilone | ***For the treatment of breast cancer. <br /> NOTE: Anthracycline resistance is defined as progression while on therapy or within 6 months in the adjuvant setting or 3 months in the metastatic setting. Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or 4 months in the metastatic setting.<br /***For the treatment of metastatic or locally advanced breast cancer that is resistant to an anthracycline and a taxane, or that is taxane resistant and for patients whom further anthracycline therapy is contraindicated, in combination with capecitabine.***For the treatment of metastatic or locally advanced breast cancer that is resistant or refractory to anthracyclines, taxanes, and capecitabine. | ***Polyoxyethylated castor oil hypersensitivity***Bone marrow suppression, neutropenia, thrombocytopenia***Hepatic disease, jaundice***Diabetes mellitus, peripheral neuropathy***Cardiac arrhythmias, cardiac disease, ventricular dysfunction***Children***Alcoholism, driving or operating machinery, substance abuse***Geriatric***Pregnancy***Breast-feeding***Radiation therapy | |||||||||||||||||||||||||||||||
| 69 | sipuleucel-T | ***For the treatment of asymptomatic or minimally symptomatic metastatic, castrate resistant (hormone refractory), prostate cancer. <br /> NOTE: Approximately 3 days prior to each infusion of sipuleucel-T, a standard leukapheresis procedure is to be done. If the patient is unable to receive an infusion of sipuleucel-T and treatment is to be continued, the patient will need to undergo an additional leukapheresis procedure.<br />NOTE: Prior to infusion of sipuleucel-T, match the patient's identity with the patient identifiers on both the Cell Product Disposition Form and the sipuleucel-T infusion bag | ***General Information***Cardiac disease, infusion-related reactions, pulmonary disease***Chemotherapy, immunosuppression***Children, infants, neonates***Pregnancy***Breast-feeding | ||||||||||||||||||||||||||||||||
| 70 | ['274771'] | nelarabine | ***For the treatment of T-cell leukemia/lymphoma.***For the treatment of T-cell leukemia/lymphoma in patients at first relapse or with refractory disease�.***For the treatment of T-cell leukemia/lymphoma in patients who have not responded to or have relapsed following treatment with at least 2 chemotherapy regimens.***For the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL)�.***Formoterol; Mometasone | ***Chemotherapy, driving or operating machinery, geriatric, neurological disease, neurotoxicity, peripheral neuropathy, radiation therapy, seizures***Bone marrow suppression, fungal infection, herpes infection, infection, varicella, viral infection***Dental disease, dental work***Intramuscular injections***Hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia***Hepatic disease***Renal failure, renal impairment***Pregnancy***Breast-feeding***Accidental exposure, ocular exposure***Vaccination | |||||||||||||||||||||||||||||||
| 71 | ['6218'] | lactulose | ***For the treatment of hepatic encephalopathy (portal-systemic encephalopathy, PSE).***For the treatment of constipation, including constipation related to barium retention. | ***Galactose-free diet***Surgery***Diabetes mellitus***Geriatric***Pregnancy***Breast-feeding | |||||||||||||||||||||||||||||||
| 72 | ['10379'] | testosterone | ***For the treatment of delayed puberty in males.***For palliative treatment of breast cancer that is inoperable in women.***For the treatment of postpubertal cryptorchidism�.***For the treatment of microphallus�.***For the treatment of anemia� in patients with chronic renal failure.***For female-to-male gender change (trans-sexualism�).***For the treatment of lichen sclerosus�.***For the treatment of AIDS-associated wasting syndrome�. | ***Benzoic acid hypersensitivity, benzyl alcohol hypersensitivity, polyoxyethylated castor oil hypersensitivity, risk of serious hypersensitivity reactions or anaphylaxis, soya lecithin hypersensitivity***Magnetic resonance imaging (MRI)***Intramuscular administration, intravenous administration***Breast cancer, geriatric, prostate cancer, prostatic hypertrophy***Cardiac disease, coronary artery disease, heart failure, hepatic disease, myocardial infarction, renal disease, stroke***Obesity, pulmonary disease***Polycythemia***Accidental exposure, females***Contraception requirements, labor, obstetric delivery, pregnancy, reproductive risk***Breast-feeding***Diabetes mellitus***Hypercalcemia***Pulmonary oil microembolism***Nasal polyps, nasal septal perforation, nasal surgery, nasal trauma, rhinorrhea, Sjogren's syndrome***Children, infants, neonates***Substance abuse***Infertility | |||||||||||||||||||||||||||||||
| 73 | levothyroxine sodium | ***For the treatment of primary hypothyroidism with or without goiter due to diminished or absent thyroid function caused by functional deficiency, primary atrophy, partial or complete absence of the thyroid gland, or from the effects of surgery, radiation, or an antithyroid agent, and for the treatment of secondary (pituitary) or tertiary (hypothalamic) hypothyroidism.***For the treatment of myxedema coma.***For thyroid stimulating hormone (TSH) suppression in thyroid nodules, euthyroid goiters, and well-differentiated thyroid cancer.***Formoterol; Mometasone | ***General Information***Adrenal insufficiency***Hypopituitarism***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, coronary artery disease, hypertension, myocardial infarction***Diabetes mellitus***Obesity treatment***Infertility***Osteoporosis***Pregnancy***Breast-feeding***Dysphagia***Geriatric | ||||||||||||||||||||||||||||||||
| 74 | diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed | ***For simultaneous diphtheria prophylaxis, tetanus prophylaxis, and pertussis prophylaxis.***For prophylaxis against diphtheria and tetanus for patients with large, contaminated wounds who also need the pertussis component. | ***Children, infants, neonates, premature neonates***Intraarterial administration, intravenous administration, subcutaneous administration***Guillain-Barre syndrome***Latex hypersensitivity***Coma, encephalopathy, neurological disease, seizure disorder, seizures***Fever, shock***Anticoagulant therapy, bleeding, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Infection***Immunosuppression***Pregnancy***Breast-feeding***Syncope | ||||||||||||||||||||||||||||||||
| 75 | ['21212'] | clarithromycin | ***For the treatment of acute exacerbations of chronic bronchitis.***For the treatment of community-acquired pneumonia (CAP).***For the treatment of sinusitis.***For the treatment of uncomplicated skin and skin structure infections.***For the treatment of acute otitis media.***For the treatment of disseminated Mycobacterium avium complex infection (MAC) <em> </em>in HIV-positive patients.***For <em>Mycobacterium avium </em>complex (MAC) prophylaxis in HIV-infected patients.***For primary <em>Mycobacterium avium</em> complex (MAC) prophylaxis.***For secondary <em>Mycobacterium avium</em> complex (MAC) prophylaxis in patients with disseminated disease, after treatment of the acute illness.***For Helicobacter pylori (H. pylori) eradication in the treatment of patients with duodenal ulcer disease (active or a history of duodenal ulcer), gastric ulcer�, dyspepsia�, or gastric mucosa associated lymphoid tissue (MALT) lymphoma�. <br /> NOTE: The American College of Gastroenterology (ACG) recommends 10 to 14 days of a triple-drug regimen containing a proton pump inhibitor (PPI), clarithromycin, and either amoxicillin or metronidazole. Although 10 to 14 days is recommended, ACG also indicates that giving therapy for 2 weeks may be preferred; a meta-analysis of more than 900 patients found that, as compared to a 7-day regimen, the rate of H. pylori eradication was significantly higher in patients taking triple therapy for 14 days (odds ratio 0.62, 95% CI 0.45 to 0.84). Although not significant, there was a trend towards improved eradication rates with 10 days of therapy vs. 7 days of therapy. The same combination for 14 days continues to be recommended as first line therapy in the 2006 global updates from the Maastricht III Consensus Report.<br />NOTE: In populations where H. pylori infection is common (10% or more), patients presenting with non-ulcer dyspepsia should be tested for H. pylori; those found to be H. pylori positive should be started on combination eradication therapy (also see Prevpac monograph). <br />NOTE: Clarithromycin resistance rates for H. pylori strains in the US are 13%. In patients who fail therapy, susceptibility testing should be done, if possible. If resistance to clarithromycin is demonstrated, a non-clarithromycin containing regimen is recommended.<br />NOTE: A large body of data exist to support the importance of H. pylori eradication as the first line treatment of gastric MALT lymphoma. After H. pylori eradication, long term tumor regression is observed in 60% to 90% of patients.***For bacterial endocarditis prophylaxis�.***For the treatment of pertussis (whooping cough)� caused by <em>Bordetella pertussis</em>.***For postexposure pertussis prophylaxis�.***For the treatment of bartonellosis� (<em>Bartonella bacilliformis)</em> and other <em>Bartonella sp.</em>� infections in HIV-infected patients.***For the treatment of angiomatosis infections�, peliosis hepatis�, bacteremia�, and osteomyelitis� caused by <em>Bartonella sp.</em>�.***For long term suppression� of infections caused by <em>Bartonella sp.</em>� in patients with relapse or reinfection with less than 200 CD4 cells/mm3.***For the treatment of pharyngitis (primary rheumatic fever prophylaxis�) or tonsillitis caused by susceptible strains of <em>Streptococcus pyogenes</em> (group A beta-hemolytic streptococci). <br /> NOTE: Clarithromycin is generally effective at eradication of S. pyogenes from the nasopharynx, however, data on the efficacy of preventing rheumatic fever are unknown. The antibiotic of choice for treatment and prevention of streptococcal infection and prophylaxis of rheumatic fever is penicillin administered either intramuscularly or orally.<br />NOTE: The American Heart Association (AHA) recommends secondary prophylaxis for 10 years or until age 40 (whichever is longer) for patients who have experienced rheumatic fever with carditis and have residual heart disease (persistent valvular disease). For patients who have experienced rheumatic fever with carditis, but have no residual heart disease, the AHA recommends prophylaxis for 10 years or until age 21 (whichever is longer). For patients who have experienced rheumatic fever without carditis, the AHA recommends prophylaxis for 5 years or until age 21 (whichever is longer)***Formoterol; Mometasone | ***General Information***Viral infection***Macrolide hypersensitivity***Pregnancy***Breast-feeding***Hepatic disease, hepatitis, jaundice***Renal failure, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Colostomy, ileostomy***Children, infants, neonates***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, mortality, myocardial infarction, QT prolongation, thyroid disease, torsade de pointes, ventricular arrhythmias***Myasthenia gravis***Geriatric | |||||||||||||||||||||||||||||||
| 76 | donepezil hydrochloride | ***For the treatment of Alzheimer's disease.***For the treatment of mild to moderate Alzheimer's disease.***For the treatment of moderate to severe Alzheimer's disease.***For the treatment of vascular dementia�.***For the short-term treatment (up to 90 days) of acute cognitive deficits following ischemic stroke�.***For the treatment of dementia with Lewy bodies�.***Formoterol***Formoterol; Mometasone | ***General Information***Abrupt discontinuation***Alcoholism, AV block, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypotension, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, sick sinus syndrome, syncope, thyroid disease***Diarrhea, GI bleeding, GI disease, peptic ulcer disease, vomiting***Hepatic disease***Asthma, chronic obstructive pulmonary disease (COPD), pulmonary disease***Bladder obstruction***Seizure disorder, seizures***Pregnancy***Breast-feeding***Children, infants, neonates***Surgery***Geriatric | ||||||||||||||||||||||||||||||||
| 77 | ['72302'] | ropinirole | ***For the treatment of Parkinson's disease.***For conversion from immediate-release to extended-release tablets.***For the treatment of restless legs syndrome (RLS). | ***General Information***Pregnancy***Breast-feeding***Children***Cardiac disease, hypertension, hypotension, orthostatic hypotension, syncope***Geriatric, psychosis***Dialysis, renal failure, renal impairment***Hepatic disease***Tobacco smoking***Coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion, narcolepsy, sleep apnea***Abrupt discontinuation***Melanoma***Impulse control symptoms | |||||||||||||||||||||||||||||||
| 78 | ['38400'] | atomoxetine | ***For the treatment of attention-deficit hyperactivity disorder (ADHD). | ***General Information***Pheochromocytoma***MAOI therapy***Hepatic disease, hepatitis, jaundice***Closed-angle glaucoma***Constipation, GI obstruction, ileus, prostatic hypertrophy, urinary retention***Seizure disorder, seizures***Driving or operating machinery, ethanol intoxication***Bipolar disorder, depression, mania, psychosis***Alcoholism, arteriosclerosis, bradycardia, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, congenital heart disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, stroke, tachycardia, thyroid disease, ventricular arrhythmias, ventricular dysfunction***Children, growth inhibition, suicidal ideation***Dehydration, hypovolemia, orthostatic hypotension, syncope***Pregnancy***Breast-feeding***Geriatric | |||||||||||||||||||||||||||||||
| 79 | ['14851'] | vigabatrin | ***For use as monotherapy in the treatment of infantile spasms in pediatric patients for whom the potential benefits outweigh the potential risk of vision loss. <br /> NOTE: Vision loss in infants and children may not be detected until it is severe. Vision assessment is recommended at baseline (no later than 4 weeks after vigabatrin initiation), at least every 3 months during therapy, and approximately 3 to 6 months after vigabatrin discontinuation.<br /***For the adjunctive treatment of refractory complex partial seizures. <br /> NOTE: Vision assessment is recommended at baseline (no later than 4 weeks after vigabatrin initiation), at least every 3 months during therapy, and approximately 3 to 6 months after vigabatrin discontinuation.<br /> ***Formoterol; Mometasone | ***General Information***Requires an experienced clinician, visual impairment***Depression, suicidal ideation***Abrupt discontinuation***Driving or operating machinery***Hepatic decompensation, hepatic disease***Renal impairment***Geriatric***Children, infants, neonates***Substance abuse***Pregnancy***Breast-feeding | |||||||||||||||||||||||||||||||
| 80 | diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine | ***For simultaneous diphtheria prophylaxis, tetanus prophylaxis, pertussis prophylaxis, and poliovirus prophylaxis as the fifth dose in the diphtheria, tetanus, and acellular pertussis (DTaP) vaccine series and the fourth dose in the inactivated poliovirus vaccine (IPV) series in children whose previous DTaP vaccine doses have been with Infanrix and/or Pediarix for the first three doses and Infanrix for the fourth dose. | ***Intraarterial administration, intravenous administration, subcutaneous administration***Guillain-Barre syndrome***Neomycin hypersensitivity, polymyxin hypersensitivity, polysorbate 80 hypersensitivity***Latex hypersensitivity***Coma, encephalopathy, fever, neurological disease, seizure disorder, seizures***Shock***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Immunosuppression***Infection***Children, infants, neonates***Pregnancy***Breast-feeding | ||||||||||||||||||||||||||||||||
| 81 | interferon gamma-1b | ***For the treatment of chronic granulomatous disease to reduce the frequency and severity of serious infections. <br /> NOTE: Interferon gamma-1b has been designated an orphan drug by the FDA for this indication.<br /> ***For the treatment of severe, malignant osteopetrosis to delay the time to disease progression. <br /> NOTE: Interferon gamma-1b has been designated an orphan drug by the FDA for this indication.<br /> | ***Pulmonary fibrosis***Bone marrow suppression, immunosuppression***Infants, neonates***Angina, cardiac arrhythmias, cardiac disease, heart failure, myocardial infarction***Driving or operating machinery, seizure disorder***E. coli protein hypersensitivity, latex hypersensitivity, mannitol hypersensitivity***Hepatic disease***Renal failure, renal impairment***Pregnancy***Breast-feeding***Infertility, reproductive risk | ||||||||||||||||||||||||||||||||
| 82 | ['73710'] | paricalcitol | ***For the prevention and treatment of secondary hyperparathyroidism and resultant metabolic bone disease (renal osteodystrophy�). <br /> NOTE: Dosage adjustments should be determined based on serum calcium, serum phosphorous, and serum or plasma iPTH concentrations. Initially and following a dosage adjustment, serum calcium, serum phosphorous, and serum or plasma iPTH concentrations should be monitored at least every 2 weeks for 3 months, monthly for 3 months, and then every 3 months thereafter.<br /> ***For initial dosing and dosage titration in pre-dialysis patients with Stage 3 or 4 chronic kidney disease. <br /> NOTE: In general, the dose should be adjusted no more frequently than every 2 to 4 weeks in adults and every 4 weeks in pediatric patients. In clinical trials of paricalcitol in adults, the average weekly dose was 9.6 mcg in patients taking once daily and 9.5 mcg in patients taking 3 times per week.<br /***For initial dosing and dosage titration in patients with Stage 5 chronic kidney disease on dialysis.***For initial dosing and dosage titration in patients with stage 5 chronic kidney disease on dialysis (National Kidney Foundation Guidelines). <br /> NOTE: Serum calcium concentration should be less than 9.5 mg/dL in patients with a serum iPTH less than 1000 pg/mL. In patients with a serum iPTH greater 1000 pg/mL, the serum calcium concentration should be less than 10 mg/dL. Serum phosphorous concentration should be less than 5.5 mg/dL and the calcium-phosphorous product should be less than 55.<br />Dosage adjustments should be determined based on serum calcium, serum phosphorous, and plasma iPTH concentrations. Initially and during dosage titration, monitor serum calcium and phosphorous concentrations every 2 weeks for 1 month and then monthly. Plasma iPTH concentration should be monitored monthly for 3 months then every 3 months once target iPTH concentrations are achieved (150 to 300 pg/mL) | ***Hypercalcemia***Hypervitaminosis D***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric | |||||||||||||||||||||||||||||||
| 83 | ['819300'] | golimumab | ***For the treatment of moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate.***For the treatment of active ankylosing spondylitis (AS).***For the treatment of active psoriatic arthritis (PsA).***For the treatment of moderately to severely active ulcerative colitis to induce and maintain clinical response, to improve endoscopic appearance of the mucosa during induction, to induce clinical remission, and to achieve and sustain clinical remission in induction responders in adults who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine. | ***Hepatitis, hepatitis B exacerbation***Bone marrow suppression, corticosteroid therapy, diabetes mellitus, fungal infection, immunosuppression, infection, influenza, mycobacterial infection, sepsis, surgery, tuberculosis, viral infection***Cholangitis, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease, leukemia, lymphoma, new primary malignancy, skin cancer, ulcerative colitis***Heart failure***Guillain-Barre syndrome, multiple sclerosis, optic neuritis***Agranulocytosis, leukopenia, neutropenia, thrombocytopenia***Latex hypersensitivity***Vaccination***Infants, neonates, pregnancy***Breast-feeding***Geriatric***Children | |||||||||||||||||||||||||||||||
| 84 | ['3008'] | cyclosporine | ***For kidney transplant rejection prophylaxis.***For kidney transplant rejection prophylaxis in combination with sirolimus and corticosteroids in patients who are considered low to moderate immunologic risk.***For kidney transplant rejection prophylaxis in combination with sirolimus and corticosteroids in patients who are considered high immunologic risk. <br /> NOTE: Black transplant recipients, repeat renal transplant recipients who lost a previous allograft for immunologic reason, or patients with high-panel reactive antibodies (PRA; peak PRA level greater than 80%) are considered high immunologic risk.<br />NOTE: The protocol-specified target Cmin range for cyclosporine was 200 to 300 ng/mL up to week 2, 150 to 200 ng/mL for weeks 2 to 26, and 100 to 150 ng/mL for weeks 26 to 52, and for sirolimus was 10 to 15 ng/mL***For the treatment of severe, plaque-type psoriasis in immunocompetent patients who failed to respond to at least one systemic therapy (e.g., PUVA, retinoids, methotrexate) or in patients for whom other systemic therapies are contraindicated or cannot be tolerated.***For the treatment of severe rheumatoid arthritis (RA) in patients unresponsive to conventional therapy, alone or in combination with methotrexate when the disease has not adequately responded to methotrexate.***For early rheumatoid arthritis (RA).***For the treatment of xerophthalmia by increasing tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.***For the treatment of heart transplant rejection prophylaxis, liver transplant rejection prophylaxis, and the treatment of acute and chronic graft-versus-host disease (GVHD)� and graft-versus-host disease (GVHD) prophylaxis�. <br /> NOTE: In general, children may undergo the same dosing regimen as adults but often require and tolerate higher doses.<br />NOTE: In the prevention of organ transplant rejection, cyclosporine is intended to be used in combination with corticosteroid therapy***For the treatment of severe atopic dermatitis�.***For the treatment of severe aplastic anemia�.***For the treatment of chronic immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP)�.***For the treatment of myasthenia gravis� in patients who are poorly controlled with cholinesterase inhibitor therapy.***For the treatment of psoriatic arthritis�.***For the treatment of lupus nephritis� in patients with systemic lupus erythematosus (SLE) unresponsive to conventional therapy, or for the treatment of children with idiopathic nephrotic syndrome�. | ***General Information***Fungal infection, herpes infection, immunosuppression, infection, requires a specialized care setting, requires an experienced clinician, varicella, viral infection***Herpes simplex keratitis (dendritic keratitis), ocular infection***Lymphoma, new primary malignancy, radiation therapy, skin cancer, sunlight (UV) exposure***Nephrotoxicity, renal disease, renal failure, renal impairment***Hyperkalemia, hypertension***Electrolyte imbalance***Polyoxyethylated castor oil hypersensitivity***Children, infants***Pregnancy***Breast-feeding***Geriatric***Alcoholism, biliary tract disease, hepatic disease, jaundice***Gout, hyperuricemia***Encephalopathy, hypomagnesemia***Vaccination***Contact lenses | |||||||||||||||||||||||||||||||
| 85 | ['68244'] | lamivudine | ***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents.***For the treatment of chronic hepatitis B infection.***For the treatment of chronic hepatitis B infection in HIV-negative patients.***For the treatment of chronic hepatitis B infection in HIV-positive patients.***For human immunodeficiency virus (HIV) prophylaxis�.***For HIV prophylaxis after occupational exposure to HIV.***For HIV prophylaxis after non-occupational HIV exposure, including sexual assault. <br /> NOTE: Higher risk exposures for which prophylaxis is recommended include exposure of vagina, rectum, eye, mouth, or other mucous membrane, nonintact skin, or percutaneous contact with blood, semen, vaginal secretions, rectal secretions, breast milk, or any body fluid that is visibly contaminated with blood when the source is known to be HIV-positive. Exposures to a source patient with unknown HIV status should be assessed on a case-by-case basis.<br /***For perinatal human immunodeficiency virus (HIV) prophylaxis� in neonates at high risk for HIV acquisition. <br /> NOTE: Empiric therapy with a 3-drug combination antiretroviral (ARV) regimen, consisting of zidovudine, lamivudine, and nevirapine at treatment doses, is a treatment option recommended for neonates with presumed HIV exposure or those at high risk for perinatal HIV transmission (neonates born to HIV-infected mothers: who have not received antepartum or intrapartum ARV treatment, who have received only intrapartum ARV treatment, who have suboptimal viral suppression near delivery, who have acute or primary HIV infection during pregnancy or breastfeeding, who have unknown HIV status, or who have known ARV drug-resistant virus). ARV therapy should be initiated as close to the time of birth as possible, preferably within 6 to 12 hours of delivery.<br / | ***General Information***Hepatitis B and HIV coinfection, hepatitis B exacerbation, HIV serum status***Alcoholism, females, hepatic disease, Hepatotoxicity or Lactic Acidosis, obesity, organ transplant***Geriatric***Peripheral neuropathy***Renal failure, renal impairment***Children, infants, neonates, pancreatitis***Pregnancy***Breast-feeding***Human immunodeficiency virus (HIV) infection resistance***Diabetes mellitus***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Hepatitis C and HIV coinfection | |||||||||||||||||||||||||||||||
| 86 | ['861634'] | pitavastatin | ***For the treatment of hypercholesterolemia, hyperlipoproteinemia, and/or hypertriglyceridemia as an adjunct to dietary control.***For reduction of elevated total cholesterol, LDL-cholesterol, apolipoprotein B, and triglyceride concentrations, and to increase HDL-cholesterol in patients with primary hypercholesterolemia or mixed dyslipidemia.***For the regression of coronary atherosclerosis in patients with acute coronary syndrome (ACS). | ***General Information***Alcoholism, cholestasis, hepatic disease, hepatic encephalopathy, hepatitis, jaundice***Dialysis, electrolyte imbalance, endocrine disease, females, hypotension, hypothyroidism, infection, myopathy, organ transplant, renal disease, renal failure, renal impairment, rhabdomyolysis, seizure disorder, surgery, trauma***Diabetes mellitus***Contraception requirements, pregnancy***Breast-feeding***Children, infants***Geriatric | |||||||||||||||||||||||||||||||
| 87 | ketotifen fumarate | ***For the temporary prevention of ocular pruritus due to allergic conjunctivitis.***For the treatment of allergic conditions including allergic rhinitis�, atopic dermatitis�, and acute or chronic urticaria�. | ***Children, infants, neonates***Contact lenses***Pregnancy***Breast-feeding | ||||||||||||||||||||||||||||||||
| 88 | moxifloxacin hydrochloride | ***For the treatment of acute bacterial exacerbation of chronic bronchitis.***For the treatment of acute bacterial sinusitis.***For the treatment of mild to moderate community-acquired pneumonia (CAP).***For the treatment of skin and skin structure infections.***For uncomplicated skin and skin structure infections due to <em>Staphylococcus aureus</em> (MSSA) and <em>Streptococcus pyogenes</em>.***For complicated skin and skin structure infections due to <em>Enterobacter cloacae</em>, <em>Escherichia coli</em>, <em>Klebsiella pneumoniae</em>, or <em>Staphylococcus aureus</em> (MSSA).***For the treatment of complicated intraabdominal infections including polymicrobial infections such as abscesses.***For the treatment of bacterial conjunctivitis (including chlamydial conjunctivitis) due to susceptible organisms.***For the treatment of plague, including pneumonic and septicemic plague, and plague prophylaxis due to susceptible isolates.***For the treatment of tuberculosis infection� caused by <em>Mycobacterium tuberculosis�</em> in combination with other antituberculosis agents as a second line agent. <br /> NOTE: The American Thoracic Society (ATS), Infectious Diseases Society of America (IDSA), and the Centers for Disease Control and Prevention (CDC) recommend short-course regimens (e.g., >= 6 months) for uncomplicated pulmonary tuberculosis and most cases of extrapulmonary tuberculosis in adults. According to the ATS, IDSA, CDC, and American Academy of Pediatrics (AAP), short-course regimens are also suitable in children. Directly observed therapy (DOT) should be used for all regimens administered 1, 2, 3, or 5 times per week. The initial treatment regimen should include four drugs unless the likelihood of INH or rifampin resistance is low (i.e., < 4%), in which case an initial regimen of INH, rifampin, and pyrazinamide may be considered. HIV-infected patients should always receive induction therapy with four drugs by DOT. When drug susceptibility results are available, the regimen should be altered as appropriate. For multi-drug resistant tuberculosis (MDR-TB), drug therapy choice should be based on specific resistance patterns. For pediatrics, the CDC recommends treatment for 18�24 months after culture conversion in patients with bacteriologic confirmation and for >= 12 months in patients who are culture-negative. The World Health Organization (WHO) recommends at least 8 months of an intensive phase of treatment with a total treatment duration of 20 months in MDR-TB.<br /> ***For the treatment of Mycobacterium avium complex infection� (MAC) in HIV-infected patients.***For the treatment of anthrax�.***For the treatment of systemic anthrax infection.***For the treatment of cutaneous anthrax infection.***For the treatment of bacterial gastroenteritis� and infectious diarrhea�.***For salmonellosis� in HIV-infected patients.***For shigellosis� in HIV-infected patients.***For the treatment of campylobacteriosis� in HIV-infected patients.***For surgical infection prophylaxis�.***For ophthalmic surgical prophylaxis�.***For the treatment of recurrent or persistent non-gonococcal urethritis (NGU)�.***For the treatment of pelvic inflammatory disease (PID)�.***For anthrax prophylaxis� after exposure to <em>Bacillus anthracis</em> (postexposure prophylaxis, PEP).***Formoterol***Formoterol; Mometasone | ***Viral infection***Quinolone hypersensitivity***Corticosteroid therapy, organ transplant, tendinitis, tendinopathy, tendon pain, tendon rupture***Alcoholism, atrial fibrillation, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease, torsade de pointes***Cerebrovascular disease, neurotoxicity, peripheral neuropathy, seizure disorder***Myasthenia gravis***Hepatic disease, hepatitis, hepatotoxicity, jaundice***Diabetes mellitus***Sunlight (UV) exposure***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Geriatric***Pregnancy***Breast-feeding***Sexually transmitted disease***Children, infants, neonates***Sodium restriction***Contact lenses***Driving or operating machinery | ||||||||||||||||||||||||||||||||
| 89 | formoterol fumarate | ***For the maintenance prevention of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. | ***Monotherapy treatment of asthma***Paradoxical bronchospasm***Acute bronchospasm, asthma-related death***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hepatic disease, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, tachycardia***Diabetes mellitus, diabetic ketoacidosis, hyperglycemia, hyperthyroidism, pheochromocytoma, seizure disorder, seizures, thyroid disease, thyrotoxicosis***Labor, pregnancy***Breast-feeding***MAOI therapy***Geriatric***Children, infants***Milk protein hypersensitivity | ||||||||||||||||||||||||||||||||
| 90 | azelaic acid | ***For the treatment of mild-to-moderate inflammatory acne vulgaris.***For the treatment of inflammatory pustules and papules of mild-to-moderate acne rosacea.***For the treatment of melasma�.***For the treatment of lentigo maligna� in which surgery is contraindicated.***For the treatment of cutaneous malignant melanoma�. | ***General Information***Occlusive dressing, ocular exposure***Pregnancy***Breast-feeding***Children, infants, neonates***Herpes infection***Asthma, deterioration of asthma | ||||||||||||||||||||||||||||||||
| 91 | ['37418', '67158'] | sumatriptan | ***For the acute treatment of migraine attacks with or without aura. <br /> NOTE: Sumatriptan is not indicated for hemiplegic or basilar migraine.<br /> ***For the acute treatment of cluster headache. | ***General Information***Sumatriptan hypersensitivity***Acute myocardial infarction, angina, arteriosclerosis, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, hypercholesterolemia, obesity, tobacco smoking, vasospastic angina, Wolff-Parkinson-White syndrome***Hypertension***Cerebrovascular disease, intracranial bleeding, stroke***Basilar/hemiplegic migraine***Intravenous administration***Pregnancy***Breast-feeding***Hepatic disease***Renal disease, renal failure, renal impairment***Children***Geriatric***Driving or operating machinery***Colitis, peripheral vascular disease, Raynaud's phenomenon***Seizure disorder, seizures***Visual disturbance***MAOI therapy***Magnetic resonance imaging (MRI) | |||||||||||||||||||||||||||||||
| 92 | ondansetron); (ondansetron hydrochloride | ***For chemotherapy-induced nausea/vomiting prophylaxis (CINV prophylaxis) and radiation-induced nausea/vomiting prophylaxis (RINV prophylaxis).***For post-operative nausea/vomiting (PONV) prophylaxis.***For the treatment of post-operative nausea/vomiting (PONV)�.***For hyperemesis gravidarum� (severe pregnancy-induced nausea/vomiting) unresponsive to other antiemetics.***For the short-term treatment of nausea/vomiting associated with acute gastroenteritis�.***For the treatment of pruritus� secondary to cholestasis.***For the maintenance treatment of alcohol dependence�.***For the treatment of cyclic vomiting syndrome�.***Formoterol***Formoterol; Mometasone | ***General Information***Hepatic disease, hepatitis***Dolasetron hypersensitivity, granisetron hypersensitivity, ondansetron hypersensitivity, palonosetron hypersensitivity***Phenylketonuria***GI obstruction, ileus***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Children***Infants, neonates***Pregnancy***Breast-feeding***Geriatric | ||||||||||||||||||||||||||||||||
| 93 | ['1116632'] | ticagrelor | ***For arterial thromboembolism prophylaxis in patients with acute coronary syndrome (ACS) (unstable angina, acute myocardial infarction), including in patients undergoing percutaneous coronary intervention (PCI). | ***General Information***Bleeding, coronary artery bypass graft surgery (CABG), GI bleeding, intracranial bleeding, surgery***Hepatic disease***Labor, obstetric delivery, pregnancy***Breast-feeding***Abrupt discontinuation***Children, infants, neonates***AV block, bradycardia, sick sinus syndrome, syncope***Aspirin coadministration***Geriatric | |||||||||||||||||||||||||||||||
| 94 | tiotropium bromide | ***For the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and to reduce exacerbations of COPD.***For the long-term maintenance treatment of asthma. | ***General Information***Milk protein hypersensitivity***Acute bronchospasm***Closed-angle glaucoma, contact lenses, ocular exposure, ophthalmic administration***Anticholinergic medications, bladder obstruction, prostatic hypertrophy, urinary retention, urinary tract obstruction***Cardiac arrhythmias***Renal impairment***Driving or operating machinery***Geriatric***Pregnancy***Breast-feeding***Children, infants | ||||||||||||||||||||||||||||||||
| 95 | ['28439'] | lamotrigine | ***For the treatment of partial seizures with or without secondary generalization. <br /> NOTE: Lamotrigine should be initiated at a low dose, with gradual increases according to the dose escalation guidelines provided by the manufacturer. This may minimize the occurrence of a severe, and potentially life-threatening skin rash, which has been associated with lamotrigine administration.<br />NOTE: Therapeutic plasma concentrations have not been established. In general, dosage should be based upon clinical response.<br />NOTE: Discontinuation of lamotrigine should be done in a step-wise fashion over at least 2 weeks (approximately 50% dosage reduction per week), unless safety concerns warrant a more rapid withdrawal***For monotherapy of partial seizures in patients currently receiving treatment with a single enzyme-inducing anti-epileptic drug (AED) (e.g., carbamazepine, phenobarbital, phenytoin, primidone) NOT to include valproate.***For monotherapy of partial seizures in patients currently receiving treatment with valproate.***For adjunctive therapy to other anticonvulsants in the treatment of partial seizures.***For monotherapy of partial seizures in patients currently receiving treatment with a single anti-epileptic drug (AED) OTHER than carbamazepine, phenytoin, phenobarbital, primidone, or valproate. <br /> NOTE: Safety and effectiveness of extended-release tablets have not been established as initial monotherapy or for simultaneous conversion to monotherapy from 2 or more concomitant AEDs.<br /***For adjunctive therapy to other anticonvulsants in the treatment of primary generalized tonic-clonic seizures. <br /> NOTE: Lamotrigine should be initiated at a low dose, with gradual increases according to the dose escalation guidelines provided by the manufacturer. This may minimize the occurrence of a severe, and potentially life-threatening skin rash, which has been associated with lamotrigine administration.<br />NOTE: Therapeutic plasma concentrations have not been established. In general, dosage should be based upon clinical response.<br />NOTE: Discontinuation of lamotrigine should be done in a step-wise fashion over at least 2 weeks (approximately 50% dosage reduction per week), unless safety concerns warrant a more rapid withdrawal***For adjunctive therapy to other anticonvulsants in the treatment of generalized seizures of Lennox-Gastaut syndrome. <br /> NOTE: Lamotrigine should be initiated at a low dose, with gradual increases according to the dose escalation guidelines provided by the manufacturer. This may minimize the occurrence of a severe, and potentially life-threatening skin rash, which has been associated with lamotrigine administration.<br />NOTE: Therapeutic plasma concentrations have not been established. In general, dosage should be based upon clinical response.<br />NOTE: Discontinuation of lamotrigine should be done in a step-wise fashion over at least 2 weeks (approximately 50% dosage reduction per week), unless safety concerns warrant a more rapid withdrawal***For the long-term maintenance treatment of bipolar disorder (bipolar I disorder) to delay the occurrence of mood episodes (i.e., depression, mania, hypomania, mixed episodes) in patients treated for acute mood episodes with standard therapy. <br /> NOTE: Do not exceed initial and subsequent dose escalations of lamotrigine due to increased risk of rash. Periodically re-assess the need for continued treatment. Lamotrigine should not be abruptly discontinued; taper downward roughly 50% per week for 2 weeks unless safety issues require a more rapid dose reduction.<br /> ***For the treatment of absence seizures�.***For long-term prophylaxis of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT)�. | ***General Information***Serious rash***Depression, suicidal ideation***Abrupt discontinuation***Driving or operating machinery***Hepatic disease***Dialysis, renal disease, renal failure, renal impairment***Cardiac disease, heart failure***Black patients***Geriatric***Children, infants, neonates***Folate deficiency, pregnancy***Breast-feeding | |||||||||||||||||||||||||||||||
| 96 | bupropion hydrochloride | ***For the treatment of major depression.***For the prevention of seasonal major depressive disorder episodes associated with seasonal affective disorder (SAD).***For use as an adjunct to psychosocial interventions in the management of tobacco cessation (smoking cessation).***For use alone to aide in tobacco cessation.***For aide with tobacco cessation using bupropion in combination with a nicotine transdermal system (NTS).***For the treatment of attention-deficit hyperactivity disorder (ADHD)�.***For use as monotherapy of attention-deficit hyperactivity disorder (ADHD)� in adults.***For the symptomatic treatment of neuropathic pain� due to various causes, including pain associated with peripheral diabetic neuropathy� or postherpetic neuralgia�.***Formoterol; Mometasone | ***General Information***Alcoholism, anorexia nervosa, benzodiazepine withdrawal, brain tumor, bulimia nervosa, diabetes mellitus, head trauma, hypoglycemia, hyponatremia, hypoxemia, intracranial mass, obesity treatment, seizure disorder, seizures, stroke, substance abuse***Children, suicidal ideation***Tics, Tourette's syndrome***Behavioral changes, bipolar disorder, depression, mania, psychiatric event, schizophrenia***MAOI therapy***Neonates, pregnancy***Breast-feeding***Hepatic disease***Renal disease, renal failure, renal impairment***Acute myocardial infarction, cardiac disease, heart failure, hypertension, tobacco smoking***Geriatric***Driving or operating machinery, ethanol intoxication***Closed-angle glaucoma, increased intraocular pressure***Abrupt discontinuation | ||||||||||||||||||||||||||||||||
| 97 | ['480167'] | lapatinib | ***For the treatment of breast cancer. <br /> NOTE: Confirm normal left ventricular ejection fraction (LVEF) before starting lapatinib. Also, evaluate LVEF during treatment, as decreases in LVEF have been reported, and the lapatinib dose may need to be reduced.<br /> ***For the treatment of patients with advanced or metastatic breast cancer, in combination with capecitabine, whose tumor overexpresses the HER2 protein and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. <br /> NOTE: Patients should exhibit disease progression on trastuzumab prior to initiating combination therapy with lapatinib and capecitabine. In a randomized, open-label study of HER2-positive metastatic breast cancer patients (n = 540), median progression free survival (PFS) and overall survival (OS) for lapatinib plus capecitabine was less than for patients treated with trastuzumab plus capecitabine (PFS: 6.6 months vs. 8 months, HR 1.3, 95% CI, 1.04 to 1.64; OS: HR 1.34, 95% CI, 0.95 to 1.92). In another randomized, open-label study of women with HER2-positive metastatic breast cancer, first-line treatment with lapatinib plus taxane-based chemotherapy also had a shorter median PFS compared with trastuzumab plus taxane-based chemotherapy (n = 652) (9 months vs. 11.3 months; HR 1.37; 95% CI, 1.13 to 1.65).<br /> ***For the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor and for whom hormonal therapy is indicated, in combination with letrozole.***For the treatment of HER2-positive, trastuzumab-refractory metastatic breast cancer� in combination with trastuzumab. | ***General Information***Serious rash***Cardiac disease, heart failure, hypertension***Hepatic disease, hepatotoxicity***Alcoholism, bradycardia, cardiac arrhythmias, coronary artery disease, diabetes mellitus, females, geriatric, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease, torsade de pointes***Pneumonitis, pulmonary disease***Asian patients, Black patients, Caucasian patients, Hispanic patients***Pregnancy***Breast-feeding***Children, infants, neonates | |||||||||||||||||||||||||||||||
| 98 | ['1100699', '1100703'] | linagliptin | ***For the treatment of type 2 diabetes mellitus in combination with diet and exercise. <br /> NOTE: Linagliptin is used as monotherapy or in combination with other drugs used to treat type 2 diabetes mellitus.<br /> ***Formoterol; Mometasone | ***Exfoliative dermatitis, history of angioedema, serious rash***Diabetic ketoacidosis, type 1 diabetes mellitus***Burns, fever, infection, surgery, trauma***Adrenal insufficiency, hypoglycemia, hypothyroidism, malnutrition, pituitary insufficiency, renal impairment***Diarrhea, gastroparesis, GI obstruction, ileus, vomiting***Hypercortisolism, hyperglycemia, hyperthyroidism***Pancreatitis***Arthralgia***Heart failure***Pregnancy***Breast-feeding***Children***Geriatric | |||||||||||||||||||||||||||||||
| 99 | ['857974', '1546030'] | saxagliptin | ***For the treatment of type 2 diabetes mellitus in combination with diet and exercise.***Formoterol; Mometasone | ***Exfoliative dermatitis, history of angioedema, serious rash***Diabetic ketoacidosis, type 1 diabetes mellitus***Burns, fever, infection, surgery, trauma***Diarrhea, gastroparesis, GI obstruction, ileus, vomiting***Pancreatitis***Hypercortisolism, hyperglycemia, hyperthyroidism***Adrenal insufficiency, hypoglycemia, hypothyroidism, malnutrition, pituitary insufficiency***Cardiac disease, heart failure***Renal disease, renal failure, renal impairment***Arthralgia***Geriatric***Pregnancy***Breast-feeding***Children | |||||||||||||||||||||||||||||||
| 100 | ['20352'] | carvedilol | ***For the treatment of heart failure (ischemic origin or cardiomyopathy).***For mild, moderate, or severe heart failure in adult patients (ischemic origin or cardiomyopathy) as a single agent or in conjunction with digoxin, diuretics, hydralazine, or ACE inhibitor therapy.***For patients with severe heart failure (NYHA Class III/IV) and referred for cardiac transplantation�.***For the treatment of heart failure in pediatric patients� (ischemic origin or cardiomyopathy) usually in conjunction with digoxin, diuretics, or ACE inhibitor therapy.***For reduction of cardiovascular mortality and morbidity in stable patients with left ventricular dysfunction (ejection fraction of 40% or higher) following acute myocardial infarction.***For the treatment of essential hypertension, either as a single agent or in combination with other antihypertensive agents.***For the treatment of angina�.***For heart rate control in patients with atrial fibrillation� or atrial flutter�. | ***Angioedema, beta-blocker hypersensitivity***Abrupt discontinuation***Hyperthyroidism, thyroid disease, thyrotoxicosis***Pheochromocytoma, vasospastic angina***Acute heart failure, AV block, bradycardia, cardiogenic shock, hypotension, orthostatic hypotension, pulmonary edema, sick sinus syndrome, ventricular dysfunction***Cerebrovascular disease***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Driving or operating machinery***Surgery***Hepatic disease***Peripheral vascular disease, renal disease, renal failure, renal impairment***Depression***Psoriasis***Myasthenia gravis***Geriatric***Diabetes mellitus, hypoglycemia***Contact lenses***Pregnancy***Breast-feeding***Children, infants, neonates |